Poster Presentations Session II
Poster Presentations Session II Monday, 31 October 2016
POSTERS SET-UP: 15:30 - 15:45
POSTERS DISPLAY HOURS: 15:45 - 19:45
POSTER AUTHOR DISCUSSION: 18:45 - 19:45
POSTERS DISMANTLE: 19:45


Poster display locations are shown below the poster codes
HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Care
PHP1
A1
RATIONING RESOURCES IN HEALTH BY INVOLVING THE PUBLIC IN PRIORITY SETTING
Farmakas A1, Theodorou M2, Kaitelidou D2
1Open University of Cyprus, Latsia, Cyprus, 2Open University of Cyprus, Latsia, Nicosia, Cyprus

PHP2
A2
WHAT EU MEAN TO THE MHRA! POTENTIAL IMPACT OF ‘BREXIT’ ON PHARMACEUTICAL REGULATION IN THE UK
Macaulay R1, Attri S2, Pandey V2, Ahuja A3
1Parexel Access Consulting, London, UK, 2Paraxel International, Chandigarh, India, 3PAREXEL Access Consulting, Chandigarh, India

PHP3
A3
MULTI-CRITERIA ASSESSMENT IN HTA PROCESS IN THE CZECH REPUBLIC: THE ROLE OF DIFFERENT STAKEHOLDERS INVOLVEMENT AND IMPACT ON APPRAISAL OF DRUGS INCLUDING ORPHANS
Ornstova E1, Mlcoch T2, Dolezalova H2, Lamblova K2, Mazalova M2, Dolezal T3
1Charles University in Prague, Hradec Kralove, Czech Republic, 2Institute of Health Economics and Technology Assessment, iHETA, Prague, Czech Republic, 3iHETA, Prague, Czech Republic

PHP4
A4
WITHDRAWN

PHP5
A5
USE OF INTERNET AND RELIABILITY OF INFORMATION OBTAINED ONLINE CONCERNING MEDICATION RISKS/SAFETY: PERCEPTIONS OF CONSUMERS IN THE U.S
Narayanan S1, Bullman WR2, Rucker NL3, Rausch P4
1Market Access Solutions, LLC, Potomac, MD, USA, 2NCPIE, Rockville, MD, USA, 3Enhance Value, Bethesda, MD, USA, 4Food and Drug Administration, Silver Spring, MD, USA

PHP6
A6
PATIENT GROUP SUBMISSIONS (PGSS) IN HEALTH TECHNOLOGY ASSESSMENT (HTA) IN SCOTLAND: PREVALENCE AND IMPACT
Hamilton KA, Griffiths M, Hanman K
Costello Medical Consulting Ltd, Cambridge, UK

PHP7
A7
MEDICATION SAFETY WARNINGS: AWARENESS, SOURCE AND ACTIONS OF CONSUMERS IN THE U.S
Narayanan S1, Bullman WR2, Rucker NL3, Rausch P4
1Market Access Solutions, LLC, Potomac, MD, USA, 2NCPIE, Rockville, MD, USA, 3Enhance Value, Bethesda, MD, USA, 4Food and Drug Administration, Silver Spring, MD, USA

PHP8
A8
CONSUMER PERCEPTION OF COMMUNICATION WITH HEALTHCARE PROFESSIONALS (HCPS) AND INFORMATION CLARITY CONCERNING NEWLY PRESCRIBED MEDICATION
Narayanan S1, Rucker NL2, Bullman WR3, Rausch P4
1Market Access Solutions, LLC, Potomac, MD, USA, 2Enhance Value, Bethesda, MD, USA, 3NCPIE, Rockville, MD, USA, 4Food and Drug Administration, Silver Spring, MD, USA

PHP9
A9
RECEIPT AND DELIVERY OF MEDICATION RISK AND SAFETY INFORMATION: PERCEPTIONS OF CONSUMERS AND HEALTHCARE PROFESSIONALS (HCPS) IN THE US
Narayanan S1, Bullman WR2, Rucker NL3, Rausch P4
1Market Access Solutions, LLC, Potomac, MD, USA, 2NCPIE, Rockville, MD, USA, 3Enhance Value, Bethesda, MD, USA, 4Food and Drug Administration, Silver Spring, MD, USA

HEALTH CARE USE & POLICY STUDIES - Diagnosis Related Group
PHP10
A10
WITHDRAWN

PHP11
A11
CURRENT REIMBURSEMENT SITUATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) IN GERMANY: WHICH STRATEGY TO SECURE ADEQUATE FUNDING?
Campion M, Bot D, Ecker T
Ecker + Ecker GmbH, Hamburg, Germany

PHP12
A12
DEVELOPMENT OF REIMBURSEMENT OF NEW EXAMINATION AND TREATMENT METHODS (NUB) IN THE GERMAN DRG-SYSTEM – ANALYSIS OF NUB APPLICATIONS AND NUB STATUS SINCE IMPLEMENTATION
Hoffmann A1, Irps S2, Kersting T3
1IGES Institut GmbH, Berlin, Germany, 2IMC Clinicon, Berlin, Germany, 3Technical University of Berlin, Berlin, Germany

HEALTH CARE USE & POLICY STUDIES - Disease Management
PHP13
A13
MANAGEMENT OF CHILDREN'S ACUTE DIARRHEA BY COMMUNITY PHARMACIES IN FIVE TOWNS OF ETHIOPIA: SIMULATED CLIENT CASE
Abebe TB1, Abegaz TM1, Belachew SA1, Gebresilassie BM1, Teni FS2, Woldie HG3
1University of Gondar, Gondar, Ethiopia, 2Addis Ababa University, Addis Ababa, Ethiopia, 3Debremarkos Teaching and Referral Hospital, Debremarkos, Ethiopia

PHP14
A14
A CRITICAL REVIEW OF MEDICATION REVIEW TOOLS FOR LONG-TERM CARE FACILITIES AND DEVELOPMENT OF A NOVEL TOOL FOR QATAR
Awaisu A
Qatar University, Doha, Qatar

PHP15
A15
PARAMETRIC AND NON-PARAMETRIC APPROACHES FOR PREDICTING BACTERIAL RESISTANCE
Arepieva M1, Kolbin A2, Kurylev A2, Balykina Y1, Spiridonova A2, Mukhina N2, Sidorenko S3
1Saint Petersburg State University, Saint Petersburg, Russia, 2First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russia, 3Research Institute for Paediatric Infections, Saint Petersburg, Russia

PHP16
A16
BIOSIMILARS: MARKET ACCESS AND MARKET PENETRATION – A COMPARISON OF FRANCE AND GERMANY
Freiberg M1, Schwarz R1, Khoury C2
1Quintiles Commercial Germany GmbH, Mannheim, Germany, 2Quintiles Advisory Services, Saint Ouen, France

HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy
PHP17
A17
HOW REAL IS “FREE PRICING” IN THE UK?
Furniss J1, Auluck J2
1GfK, Melton Mowbray, UK, 2GfK, London, UK

PHP18
A18
PHARMACEUTICAL POLICIES IN EURASIAN ECONOMIC UNION COUNTRIES
Kostyuk A1, Nurgozhin T2, Akanov A3
1Kazakh Agency for Health Technology Assessment, Astana, Kazakhstan, 2Nazarbayev University, National Laboratory Astana, Astana, Kazakhstan, 3Astana Medical University, Astana, Kazakhstan

PHP19
A19
ACCESS TO ANTI-INFECTIVE MEDICINES FOR SYSTEMIC USE IN ARMENIA
Sevikyan A
Yerevan State Medical University, Yerevan, Armenia

PHP20
A20
THE ASSESSMENT OF ADVANCED MEDICINAL PRODUCTS (ATMP) IN GERMANY: IS THE PRACTICE TO DEFINE ATMP DRUGS AS PROCEDURES IN COMPLIANCE WITH EUROPEAN LEGISLATION?
Volmer T, Bakker K
SmartStep Consulting GmbH, Hamburg, Germany

PHP21
A21
ACCESS TO ORPHAN DRUGS IN POLAND - IS CHANGE IN HEALTH TECHNOLOGY ASSESSMENT APPROACH REQUIRED?
Caban A1, Lach S1, Rémuzat C2, Toumi M3
1Creativ-Ceutical, Cracow, Poland, 2Creativ-Ceutical, Paris, France, 3Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP22
A22
THE SHIFT FROM A COMPASSIONATE DRUG USE TO THE COMMON MARKET–ACCESS PROCESS: AN INFLATIONARY NO MAN’S LAND?
Loubiere A, Degrassat-Théas A, Parent de Curzon O, Paubel P
General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

PHP23
A23
FUNDING EXPENSIVE DRUGS IN HOSPITALS: WHERE IS FRANCE GOING?
Cousseau R1, Degrassat-Théas A1, Parent de Curzon O1, Paubel P2
1General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 2AP-HP, AGEPS, Paris, France

PHP24
A24
ASSESING THE AVERAGE PRICE LEVEL OF GENERICS IN GREECE AND OTHER COMPARABLE EUROPEAN COUNTRIES RELATIVE TO THEIR VOLUME MARKET SHARE
Papadopoulos C1, Lolos D2, Ollandezos M1
1Panhellenic Union of Pharmaceutical Industry, Athens, Greece, 2Imshealth, Athens, Greece

PHP25
A25
IMPACT OF US HEALTH EXCHANGES (HIX) ON THE PHARMACEUTICAL INDUSTRY
Young KE1, Soussi I2, Kornfeld A3, Toumi M4
1Creativ-Ceutical, Milan, Italy, 2Creativ-Ceutical, Tunis, Tunisia, 3Creativ-Ceutical, Paris, France, 4Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP26
A26
WHAT HAPPENS TO ORIGINATOR MEDICINES WHEN (GENERIC) FOLLOWERS ENTER THE PUBLIC MARKET
Habl CA1, Leopold C2
1Austrian Public Health Institute GÖG, Vienna, Austria, 2Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, USA

PHP27
A27
MARKET EXCLUSIVITY PERIODS AND PATENT CHALLENGES IN PHARMACEUTICALS IN SOUTH KOREA
Park H1, Lee T2
1Ministry of Food and Drug Safety, Cheongju-si, South Korea, 2Seoul National University, Seoul, South Korea

PHP28
A28
IMPLICATION OF EXTERNAL PRICE REFERENCING ON PHARMACEUTICAL LIST PRICES IN EUROPE
Csanadi M1, Prins CP2, Grélinger E3, Fricke F4, Fuksa L5, Tesar T6, Manova M7, Lorenzovici L8, Kiss A3, Kaló Z9
1Syreon Research Institute, Budapest, Hungary, 2Utrecht University, Department of Pharmaceutical Sciences, Utrecht, The Netherlands, 3National Health Insurance Fund Administration, Budapest, Hungary, 4Technische Hochschule Nürnberg, Nürnberg, Germany, 5Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Hradec Králové, Czech Republic, 6Department of Organisation and Management in Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia, 7National Council on Prices and Reimbursement of Medicinal Products, Sofia, Bulgaria, 8Syreon Research Romania, Tirgu Mures, Romania, 9Eötvös Loránd University (ELTE), Budapest, Hungary

PHP29
A29
INNOVATION : A VALUE FOR HEALTH AND GROWTH, AN INTERNATIONAL STUDY ON MARKET ACCESS STAKES FOR THERAPEUTIC INNOVATION
Berard I1, Ginestet M2, Auvray F2, Sublet G1, Bouchara G1
1NEXTEP, PARIS, France, 2AGIPHARM, Paris, France

PHP30
A30
BIOSIMILAR INFLIXIMAB: FEEDBACK AFTER A NINE MONTHS EXPERIENCE OF THEIR USE IN THE 37 PUBLIC HOSPITALS OF PARIS
Bocquet F, Degrassat-Théas A, Cordonnier A, Raybaut C, Parent de Curzon O, Fusier I, Paubel P
AP-HP, AGEPS, Paris, France

PHP31
A31
PRICE AND UTILIZATION OF NEW DRUGS UNDER A SINGLE PUBLIC PAYER SYSTEM: EVIDENCE FROM TAIWAN
LIU Y1, Lu CY2
1National Cheng Kung University, Tainan, Taiwan, 2Harvard Medical School, Boston, MA, USA

PHP32
A32
EVALUATION OF THE VALUE OF PHARMACEUTICAL PRODUCTS IN TAIWAN
Fang CH1, Chang CJ2
1Taiwan Society of Pharmacoeconomics and Outcome Research, Tao-Yun, Taiwan, 2Taiwan Society of Pharmacoeconomics and Outcome Research, TaoYuan, Taiwan

PHP33
A33
AN ASSESSMENT OF BIOSIMILARS’ BEHAVIOUR IN THE EU-5 COUNTRIES
Planellas L1, Solozabal M1, Manganelli A2, Rebollo P3, Puig-Junoy J2
1IMS Health, Barcelona, Spain, 2CRES - Universitat Pompeu Fabra, Barcelona, Spain, 3HEOR-RWE, IMS Health, Barcelona, Spain

PHP34
A34
SYSTEMIC SOLUTIONS, LEGISLATIVE AND ORGANIZATIONAL FRAMEWORKS AIMED TO PREVENT OR MITIGATE DRUG SHORTAGES IN EUROPEAN COUNTRIES
Bochenek T1, Godman BB2, Bucsics A3, De Weerdt E4, Fürst J5, Gailite E6, Hotvedt TA7, Huys I4, Inotai A8, Joppi R9, Malaj A10, Margus K11, Marković-Peković V12, Simoens S4, Slaby J13, Sović Brkičić L14, Gürpınar EU15, Vella Bonanno P16, Warminska EJ17, Pilc A18
1Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland, 2Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK, 3University of Vienna, Vienna, Austria, 4KU Leuven, Leuven, Belgium, 5ZZZS (Health Insurance Institute of Slovenia), Ljubljana, Slovenia, 6State Agency of Medicines, Riga, Latvia, 7Norwegian Medicines Agency, Oslo, Norway, 8Syreon Research Institute, Budapest, Hungary, 9Local Health Unit of Verona – Veneto Region, Verona, Italy, 10University of Medicine Tirana, Tirane, Albania, 11Estonian State Agency of Medicines, Tartu, Estonia, 12Ministry of Health and Social Welfare, Banja Luka, Republic of Srpska, Bosnia and Herzegovina, 13State Institute for Drug Control, Prague, Czech Republic, 14Croatian Health Insurance Fund, Zagreb, Croatia, 15Turkish Medicines and Medical Devices Agency, Ankara, Turkey, 16, Mellieha, Malta, 17, Warsaw, Poland, 18Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

PHP35
A35
ASSESSMENT OF CORE DRUG USE INDICATORS USING WHO/INRUD METHODOLOGY AT PRIMARY HEALTH CARE CENTERS IN BAHAWALPUR, PAKISTAN
Atif M, Qamar-Uz-Zaman M, Rehan Sarwar M, Azeem M
The Islamia University of Bahawalpur, Bahawalpur, Pakistan

PHP36
A36
BIOSIMILAR INFLIXIMAB IN THE 37 PUBLIC HOSPITALS OF PARIS: MEETING THE CHALLENGE OF SUBSTITUTION
Bocquet F1, Fusier I1, Cordonnier A1, Poisson N2, Parent de Curzon O1, Degrassat-Théas A1, Paubel P1
1AP-HP, AGEPS, Paris, France, 2General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

PHP37
A37
THE IMPACT OF REGIONAL LEGISLATIVE MEASURES ON THE PRESCRIPTION OF OFF-PATENT MEDICINES
Tettamanti A, Urbinati D, Tucci C
IMS Health, Milano, Italy

PHP38
A38
COMPARISON OF BIOSIMILAR GUIDELINE AND REAL CONSUMPTION AMONG ITALIAN REGIONS
Tettamanti A, Urbinati D, Tucci C
IMS Health, Milano, Italy

PHP39
B1
OPPORTUNITIES FOR PHARMACEUTICAL COMPANIES TO SUCCESSFULLY LAUNCH PRODUCTS IN AFRICAN COUNTRIES
Mukku S1, Edathodu A1, Dass R2, Gonzalez AO1
1Access Infinity Ltd, London, UK, 2University of Cambridge, Cambridge, UK

PHP40
B2
HAS ACCESS TO INNOVATIVE THERAPIES IN POLAND IMPROVED FOLLOWING THE 2012 REIMBURSEMENT ACT?
Jaros P1, Kapuśniak A1, Kornfeld Å2, Toumi M3
1Creativ-Ceutical, Kraków, Poland, 2Creativ-Ceutical, Paris, France, 3Aix-Marseille University, Marseille, France

PHP41
B3
THE UK EARLY ACCESS TO MEDICINES SCHEME: A 2-YEAR STATUS UPDATE ON SUCCESSES, ISSUES AND CONTROVERSIES
Macaulay R
Parexel Access Consulting, London, UK

PHP42
B4
CONTRASTING THE CHARACTERISTICS OF HTA SUBMISSIONS FOR RARE VERSUS ULTRA-RARE DISEASES
Richter T1, Janoudi G1, Nestler-Parr S2, Sehgal C1
1CADTH, Ottawa, ON, Canada, 2Roboleo & Co Ltd, London, UK

PHP43
B5
DOMESTIC MANUFACTURING IN RUSSIA: MEASURING THE SUCCESS OF THE PHARMA 2020 PROGRAM
Privolnev Y
Decision Resources Group, Toronto, ON, Canada

PHP44
B6
ARE WE INDEED FAST ADOPTERS AS WE CLAIM TO BE? AN ANALYSIS OF THE TIME INTERVAL FROM REGULATORY APPROVAL TO COVERAGE AND REIMBURSEMENT IN THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL
Ribalov R, Morginstin T, Greenberg D
Ben-Gurion University of the Negev, Beer-Sheva, Israel

PHP45
B7
DO PHARMACEUTICAL COST CONTROL POLICIES EFFECTIVE IN REDUCING PHARMACEUTICAL EXPENDITURE AND VOLUME? A SYSTEMATIC REVIEW
Lee KS1, Hendrie D2, Sunderland B2, Moorin RE3
1Ministry of Health Malaysia, Selangor, Malaysia, 2Curtin University, Western Australia, Australia, 3Curtin University, Perth, Australia

PHP46
B8
INTERNATIONAL REFERENCE PRICING: MEASURING COUNTRY INFLUENCE
Privolnev Y
Decision Resources Group, Toronto, ON, Canada

PHP47
B9
THE FUTURE OF UK DRUG PRICING: THE 2014 PPRS (AN INTERIM REVIEW)
Macaulay R
Parexel Access Consulting, London, UK

PHP48
B10
THE TRANSPARENCY OF PUBLISHED RECOMMENDATIONS ON REIMBURSEMENT OF HEALTH TECHNOLOGIES IN POLAND
Bochenek T1, Kocot E1, Rodzinka M1, Godman B2, Maciejewska K1, Kamal S3, Pilc A4
1Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland, 2Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden, 3School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneve 4, Switzerland, 4Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

PHP49
B11
ITALIAN TIMINGS IN NEW DRUGS APPROVAL: AN UP-TO-DATE ANALYSIS
Lanati EP, Lidonnici D, Ronco V
MA Provider Srl, Milano, Italy

PHP50
B12
DEVELOPMENT OF PREDICTIVE MODELS FOR THE ANALYSIS OF THE LIST OF VITAL ESSENTIAL AND NECESSARY DRUGS COMPILATION
Kolbin A1, Prasolov A2, Maksimkina E3, Balykina Y2, Golant Z4, Polushin Y1, Kurylev A1, Vilum I1
1First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russia, 2Saint Petersburg State University, Saint Petersburg, Russia, 3Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation, 4Saint Petersburg State Chemical-Pharmaceutical Academy, Saint Petersburg, Russian Federation

PHP51
B13
EARLY BENEFIT ASSESSMENT OF DRUGS AND THE VALUE-BASED HEALTHCARE CONCEPT – A QUALITATIVE INQUIRY WITHIN THE PHARMACEUTICAL INDUSTRY
Martschinke B, Traut A
EBS Business School, Oestrich-Winkel, Germany

PHP52
B14
ACCESS TO INNOVATIVE MEDICINES IN THE CZECH REPUBLIC: LENGTH OF PRICE AND REIMBURSEMENT (P&R) PROCEDURES
Klimes J, Fuksa L, Vocelka M
Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Hradec Králové, Czech Republic

PHP53
B15
DRUG PRICING AND REIMBURSEMENT PROCESSES IN ALGERIA
Soualmi R1, Bouabidi A2, Djahdou Z2, Ziouani S3, Kaddar M1, Mansouri K2
1ISPOR Chapter Algeria, Algiers, Algeria, 2Algiers University, Algiers, Algeria, 3Univ Paris-Sud, Faculty of Pharmacy, GRADES, Châtenay-Malabry, France

PHP54
B16
ARBITRATION BOARD SETTING REIMBURSEMENT AMOUNTS FOR PHARMACEUTICAL INNOVATIONS IN GERMANY WHEN PRICE NEGATIONS BETWEEN PAYORS AND MANUFACTURERS FAIL: AN EMPIRICAL ANALYSIS OF 5 YEARS' EXPERIENCE
Dintsios C1, Ludwig S2
1Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, 2HGC, Düsseldorf, Germany

PHP55
B17
THE EVOLUTION AND COMPARISON OF HTA ASSESMENT ORGANISATIONS IN SELECTED EUROPEAN COUNTRIES
Beletsi A, Koutrafouri V, Karampli E, Pavi E
National School of Public Health, Athens, Greece

PHP56
B18
DOES REAL WORLD EVIDENCE SUPPORT CONCLUSIONS FROM EXPERIMENTAL EVIDENCE IN DECISION-MAKING PROCESSES IN POLAND?
Wilk N1, Wierzbicka N2, Skrzekowska-Baran I2, Moćko P1, Tomassy J1, Kloc K1
1Arcana Institute, Kraków, Poland, 2Janssen-Cilag Polska, Warsaw, Poland

PHP57
B19
REAL WORLD EVIDENCE IN DECISION-MAKING PROCESSES ON PUBLIC FUNDING OF DRUGS IN POLAND
Wilk N1, Wierzbicka N2, Skrzekowska-Baran I2, Tomassy J1, Kloc K1, Stankowicz P1, Włodek A1
1Arcana Institute, Kraków, Poland, 2Janssen-Cilag Polska, Warsaw, Poland

PHP58
B20
MARKET UPTAKE OF PHARMACEUTICAL INNOVATIONS IN GERMANY - REGULATORY APPROACHES AND ITS CONSEQUENCES
Witte J, Greiner W
School of Public Health, Bielefeld University, Bielefeld, Germany

PHP59
B21
HEALTH TECHNOLOGY ASSESSMENT IN BRAZIL: METRICS FROM THE REPORTS OF THE NATIONAL COMMISSION FOR INCORPORATION OF TECHNOLOGIES (CONITEC)
Lemmer T, Piedade AD, de Oliveira RW, Moreira Ed, Julian G
Evidências - Kantar Health, São Paulo, Brazil

PHP60
B22
PHARMACEUTICAL INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF DRUGS IN GERMANY
Dintsios C1, Schlenkrich S2
1Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, 2University of Applied Science Zittau/Görlitz, Görlitz, Germany

PHP61
B23
COMPARING THE SAFETY PROFILES OF BIOSIMILARS WITH THEIR ORIGINATORS’: A CROSS SECTIONAL ANALYSIS ON THE EU-RMP
Lepelaars LR1, Renda F2, Mantel AK1, Trotta F2
1Utrecht University, Utrecht, The Netherlands, 2Italian Medicines Agency, Rome, The Netherlands

PHP62
B24
ASSESSMENT OF REGIONAL LEGISLATION RELATED TO THE USE OF SIMILAR BIOLOGICAL MEDICINAL PRODUCTS: THE ITALIAN CASE STUDY
Iorio A1, Lanati EP2
1MA Provider Srl, Milan, Italy, 2MA Provider Srl, Milano, Italy

PHP63
B25
COSTS, OUTCOMES AND USES OF NEW DRUGS: DRUG ASSESSMENT REPORTS VS REAL WORLD DATA
Echeverría A, Irigoyen I, Burgui C, Idoate AI, Torroba B, Idoate A, Ortega A
Clínica Universidad de Navarra, Pamplona, Spain

PHP64
B26
TREND OF ANTIDEPRESSANT UTILIZATION IN IRAN, 2006- 2015
Soleymani F1, Taheri F2
1Tehran University of Medical Sciences, Tehran, Iran, 2Minitry of Health, tehran, Iran

PHP65
B27
TRENDS IN OUTPATIENT USE OF ANTIBIOTICS IN CROATIA
Bencina G
GSK, Zagreb, Croatia

PHP66
B28
GENERIC DRUG UTILIZATION AMONG THE ELDERLY WITH MULTIPLE CHRONIC CONDITIONS IN THE UNITED STATES
Xu Y
University of Southern California, Los Angeles, CA, USA

PHP67
B29
THE BEHAVIOUR OF PHARMACISTS IN PUBLIC PHARMACIES IN RELATION TO THE COLD REGIME DRUGS
Milosević Georgiev A1, Krajnovic D1, Marinkovic V1, Tasic L1, Arsic J2, Manojlovic J1
1University of Belgrade, Belgrade, Serbia, 2Materna medika, Vranje, Serbia

PHP68
B30
TIME TRENDS IN SEQUENCE OF DRUG LAUNCH ACROSS EU5
Gubbels L, Dekkers R, Nijhuis T
Quintiles Advisory Services, Hoofddorp, The Netherlands

PHP69
B31
EXPLORING DETERMINANTS OF POLYPHARMACY IN THE ELDERLY POPULATION IN AUSTRIA
Mayer S1, Vogler S2, Simon J1, Österle A3
1Medical University of Vienna, Vienna, Austria, 2Gesundheit Österreich GmbH / Austrian Public Health Institute, Vienna, Austria, 3Vienna University of Economics and Business, Vienna, Austria

PHP70
B32
REGIONAL TIME TO MARKET OF INNOVATIVE DRUGS IN ITALY
Mantuano M, Daniel F, Urbinati D
IMS Health, Milano, Italy

PHP71
B33
PARALLEL EXPORT AND ITS IMPACT ON AVAILABILITY OF DRUGS IN SLOVAKIA
Psenkova M1, Mackovicova S1, Holocsi L1, Klapac J1, Sedlakova K2
1Pharm-In Ltd, Bratislava, Slovakia, 2Faculty of Pharmacy, Comenius University, Bratislava, Slovakia

PHP72
B34
UTILIZATION AND COST OF ANTIMICROBIALS USED IN MEDICINE AND SURGERY DEPARTMENTS OF A TERTIARY CARE TEACHING HOSPITAL
Haligeri Veerana Goud B, Roy V
Maulana Azad Medical College, University of Delhi, New Delhi, India

PHP73
B35
ECONOMIC RESOURCES OPTIMISATION IN THE HCV SETTING: THE ROLE OF THE DAAS
Garagiola E1, Ferrario L1, Croce D1, Menzaghi B2, Quirino T2, Rizzardini G3, Foglia E1
1LIUC University, Castellanza, Italy, 2ASST Valle Olona, Busto Arsizio, Italy, 3ASST Fatebenefratelli Sacco, Milano, Italy

PHP74
B36
INDUSTRIAL LANDSCAPE AND MARKET UPTAKE MODELS OF BIOSIMILARS AND OFF-PATENT BIOLOGICAL MEDICINES
Moorkens E1, Meuwissen N1, Huys I1, Vulto A2, Declerck P1, Simoens S1
1KU Leuven, Leuven, Belgium, 2The Erasmus University Medical Center, Rotterdam, The Netherlands

PHP75
B37
PRESCRIBING BEHAVIOUR AND DRUG USE IN PAKISTAN
Aziz MM1, Ji W1, Gillani AH1, Raza MA2, Fang Y1
1Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China, Xi'an, China, 2Bahauddin Zakariya University Multan, Multan, Pakistan

PHP76
B38
CHANGING OF PRESCRIPTIONS FOR DIABETES, HYPERLIPIDEMIA, AND HYPERTENSION, FROM GENERIC DRUGS TO PROTECTED BRAND DRUGS : A RETROSPECTIVE COHORT STUDY USING A NATIONAL INPATIENT DATABASE IN JAPAN
Shimizu S
Institute for Health Economics and Policy, minato-ku Tokyo, Japan

HEALTH CARE USE & POLICY STUDIES - Equity and Access
PHP77
C1
RACIAL DISPARITIES IN ACCESS TO PHARMACY AND ITS SERVICES IN PENNSYLVANIA
Pednekar P1, Peterson AM2
1University of the Sciences, Philadelphia, PA, USA, 2University of the Sciences in Philadelphia, Philadelphia, PA, USA

PHP78
C2
REVIEW OF NATIONAL POLICIES FOR RARE DISEASES ACROSS EU COUNTRIES
Garcia Sanchez JJ, Hill CE, Hill CA
MAP BioPharma Limited, Cambridge, UK

PHP79
C3
COMPARISON OF THE RELATIONSHIP BETWEEN SOCIO-ECONOMIC STATUS AND HEALTH-RELATED QUALITY OF LIFE AMONGST ATOPIC DERMATITIS PATIENTS ACROSS DIFFERENT HEALTHCARE SYSTEMS
Papsch RB, Howe T, Vrabcheva T
GfK UK, London, UK

PHP80
C4
TRANS-PACIFIC PARTNERSHIP AGREEMENT AND ITS IMPACT ON ACCESSIBILITY AND AFFORDABILITY OF MEDICINES: A META-SYNTHESIS
Yap YY1, Wong CP1, Khan TM1, Lee KS2, Ming LC3
1Monash University Malaysia, Sunway, Malaysia, 2Ministry of Health Malaysia, Selangor, Malaysia, 3University of Tasmania, Hobart, Australia

PHP81
C5
PREDICTING ORPHAN DESIGNATION AND MARKETING AUTHORISATION BASED ON A REVIEW OF THE EUROPEAN MEDICINES AGENCY ORPHAN DISEASE REGISTER
Garcia Sanchez JJ, Hill CA, Hill D
MAP BioPharma Limited, Cambridge, UK

PHP82
C6
PRELIMINARY EVALUATION OF “INTRODUCING IMMIGRANTS TO THE HEALTHCARE SYSTEM IN CHILE” PILOT PROGRAMME
Chepo M1, Cabieses B1, Bernales M1, MacIntyre AM1, Espinoza MA2
1Universidad del Desarrollo, Santiago, Chile, 2Pontificia Universidad Catolica de Chile, Santiago, Chile

PHP83
C7
MARKOV MODEL PROJECTION OF REGIONAL PHYSICIAN SUPPLY IN TURKEY SHOWS THAT PHYSICIAN DENSITY WILL NOT CHANGE SUBSTANTIALLY IN THE NEXT 15 YEARS
Jansen I, Saka Ö
Deloitte, Diegem, Belgium

PHP84
C8
THE COORDINATION OF CARE IN PMAQ-AB: AN ANALYSIS BASED ON THE ITEM RESPONSE THEORY
Souza MF, Santos Ad, Matta Machado AT, Reis IA, Santos MA, Andrade EI, Cherchiglia ML
Federal University of Minas Gerais, Belo Horizonte, Brazil

PHP85
C9
WITHDRAWN

PHP86
C10
SELF-REPORTED CLIENT SATISFACTION IN THE PRIMARY CARE DEVELOPMENT MODEL PROGRAMME
Merész G, Bálity C, Sinkó E, Dózsa KM
Semmelweis University, Budapest, Hungary

PHP87
C11
MEASURING INCOME-RELATED INEQUITY IN SELF-ASSESSED HEALTH USING THE EQ-5D IN 7 COUNTRIES
Szende A1, Janssen B2, Ramos Goñi JM2, Cabases JM3
1Covance, Leeds, UK, 2EuroQol Research Foundation, Rotterdam, The Netherlands, 3University of Navarra, Pamplona, Spain

PHP88
C12
WITHDRAWN

PHP89
C13
CASE DURATION AS A SURGICAL QUALITY AND EFFICIENCY INDICATOR IN SURGICAL RESIDENCY TRAINING PROGRAMS
Semien GA1, Gobrial W2, Stahl J3
1Cleveland Clinic Florida, Miami Shores, FL, USA, 2Cleveland Clinic Florida, Weston, FL, USA, 3University of Arizona, Tucson, AZ, USA

PHP90
C14
MARKET ACCESS IN THE CONTEXT OF ECONOMIC CRISIS: INSIGHTS FROM SEVERAL EUROPEAN COUNTRIES
Olariu E, Papageorgakopoulou C, Solaman DA, Fox D
PHMR Ltd, London, UK

PHP91
C15
PHARMACEUTICAL PRICING STRATEGIES IN DEVELOPING COUNTRIES: A SYSTEMATIC REVIEW
Mohamed Ibrahim MI1, Abdel Rida NM2, Babar ZU3, Owusu Y2
1College of Pharmacy, Qatar University, Doha, Qatar, 2Qatar University, Doha, Qatar, 3The University of Auckland, Auckland, New Zealand

HEALTH CARE USE & POLICY STUDIES - Formulary Development
PHP92
C16
THE 2016 US PAYOR LANDSCAPE: RESULTS FROM A SURVEY OF MEDICAL AND PHARMACY DIRECTORS ON FORMULARY MANAGEMENT
Brook RA1, Smeeding JE2, McManama SH3, Carlisle JA3, Sax MJ3
1The JeSTARx Group & NPRT, Newfoundland, NJ, USA, 2The TPG-NPRT & JeSTARx, Glastonbury, CT, USA, 3The Pharmacy Group, Glastonbury, CT, USA

PHP93
WITHDRAWN

PHP94
C17
DO SCOTTISH FORMULARY DECISIONS MATCH RECOMMENDATIONS MADE BY THE SMC?
Beale RC, Kusel J
Costello Medical Consulting Ltd, Cambridge, UK

PHP95
C18
GLOBAL VALUE DOSSIERS (GVDS): HOW TO ENSURE THE VALUE ISN’T LOST IN TRANSLATION
Sarnes E, Shields K, Kaufman S, Meyer KL
Xcenda, LLC, Palm Harbor, FL, USA

HEALTH CARE USE & POLICY STUDIES - Health Care Costs & Management
PHP96
C19
COST OF LOST PRODUCTIVITY DUE TO PREMATURE, SUICIDE-RELATED MORTALITY IN POLAND
Orlewska K
Medical University of Warsaw, Warsaw, Poland

PHP97
C20
SPECIALTY PHARMACY, DIAGNOSTIC, AND GENETIC TESTING COVERAGE IN THE UNITED STATES
Brook RA1, McManama SH2, Sax MJ2, Smeeding JE3
1The JeSTARx Group & NPRT, Newfoundland, NJ, USA, 2The Pharmacy Group, Glastonbury, CT, USA, 3The TPG-NPRT & JeSTARx, Glastonbury, CT, USA

PHP98
C21
RELEVANCE AND ECONOMIC CONSEQUENCES OF MEDICINE WASTE IN VIENNA: ANALYSIS OF A HOUSEHOLD GARBAGE SAMPLE
de Rooij RH1, Frederix GW1, Hövels AM1, Vogler S2
1Utrecht University, Utrecht, The Netherlands, 2Gesundheit Österreich GmbH / Austrian Public Health Institute, Vienna, Austria

PHP99
C22
A SYSTEMATIC REVIEW: ECONOMIC BURDEN OF NEEDLESTICK INJURIES ON HEALTHCARE WORKERS
Huang HL1, Lim J2, Ma A1, Li H1
1China Pharmaceutical University, Nanjing, China, 2China Europe International Business School, Shanghai, China

PHP100
C23
THE CLINICAL AND PHARMACOECONOMIC CHALLENGES FOR SECURING REIMBURSEMENT AND ACCESS TO CDX IN THE EU
Senatore P1, Oshinowo B2, Duttagupta S2, Armeni P3, Chalmers M1
1CBPartners, London, UK, 2CBPartners, New York, NY, USA, 3Bocconi University, Milano, Italy

PHP101
C24
MARKET POTENTIAL OF A NEW INFLIXIMAB BIOSIMILAR IN THE EUROPEAN MARKET: A BUDGET IMPACT ANALYSIS IN FRANCE, ITALY AND THE UK
Psachoulia E1, Martin-Rinconada MC1, Bresson A2, Negrini C3, Keady S4
1Biogen International GmbH, Zug, Switzerland, 2Biogen France, Nanterre, France, 3Biogen Italia S.r.l., Milan, Italy, 4Biogen Idec Ltd, Maidenhead, UK

PHP102
C25
THE IMPACT OF POLICY AND DEMOGRAPHIC VARIABLES ON FUTURE PRESCRIPTION COSTS FOR A PUBLICLY FUNDED HEALTH SCHEME IN IRELAND
ConwayLenihan A1, Woods N2
1Cork Institute of Technology, Cork, Ireland, 2University College Cork, Cork, Ireland

PHP103
C26
FACTORS AFFECTING PHARMACEUTICAL EXPENDITURES: A SYSTEMATIC REVIEW & ECONOMIC MODELLING FOR GREECE
Maniadakis N1, Kourlaba G2, Zavali M1, Zampoulakis D3, Kourkouni E2, Mylonas C1
1National School of Public Health, Athens, Greece, 2Collaborative Center of Clinical Epidemiology and Outcomes Research (CLEO), Non-Profit Civil Partenrship, Athens, Greece, 3State University of New York at Stony Brook (SUNY Stony Brook), New York, NY, USA

PHP104
C27
COSTS AND OUTCOMES OF HOSPITAL INFECTIONS IN ITALY
Bini C1, Sciattella P1, Marcellusi A2, Mennini FS3
1Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy, 2National Research Council (CNR), Rome, Italy, 3University of Rome Tor Vergata, Rome, Italy

PHP105
C28
HEALTH EXPENDITURE BY DISEASE AGE AND GENDER IN GREECE
Siskou O1, Schneider M2, Craig M3, Kaitelidou D4, Priftis C5, Kani C5, Litsa P5, Galanis P1, Lemonidou C6, Vafeiadis J5, Aggouris G5, Liaropoulos L1
1Center for Health Services Management and Evaluation, National and Kapodistrian University of Athens, Athens, Greece, 2BASYS, Augsburg, Germany, 3IGSS Inspection Générale de la Sécurité Sociale, Edinburgh, UK, 4Open University of Cyprus, Latsia, Nicosia, Cyprus, 5EOPYY-National Organization for Health Care Provision, Marousi, Greece, 6National and Kapodistrian University of Athens, Athens, Greece

PHP106
C29
BUDGET IMPACT ANALYSIS OF SECUKINUMAB IN MODERATE TO SEVERE PLAQUE PSORIARIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS IN FRANCE
Duteil E, Rachdi L, Cariou C, Benjamin K, Leiba G, Duco J
Novartis Pharma, Rueil-Malmaison, France

PHP107
C30
COST-SHARING IN HEALTHCARE: AN APPROACH FOR PHARMACEUTICAL CARE IN GREECE
Kyriopoulos I, Petropoulou A, Naoum V, Oikonomou N, Athanasakis K, Kyriopoulos J
National School of Public Health, Athens, Greece

PHP108
C31
SHORT AND LONG TERM COSTS ASSOCIATED WITH DIFFERENT CARDIOVASCULAR EVENTS IN BELGIUM
Caekelbergh K1, Chevalier P1, Lamotte M1, Kutikova L2, Schutyser E3, Annemans L4
1IMS Health, Zaventem, Belgium, 2Amgen (Europe) GmbH, Zug, Switzerland, 3nv Amgen sa, Brussels, Belgium, Brussels, Belgium, 4Ghent University - Brussels University, Ghent, Belgium

PHP109
WITHDRAWN

PHP110
C32
A REVIEW OF THE QUALITY AND ACCURACY OF BUDGET IMPACT MODELS FOR HIGH COST DRUGS IN IRELAND
Lucey S1, Tilson L1, Fogarty E1, Walshe V2, Barry M1
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Health Service Executive, Cork, Ireland

PHP111
C33
COST OF TOTAL PARENTERAL NUTRITION SERVICES AT MINISTERY OF HEALTH IN SAUDI ARABIA
Alomi YA1, Fallatah AO2, Al-Smail EH2, Al-Yahya MF2, Al-Shubbar NA2, Al-Enazi AD2, Al-Qatany K2, Al-Enazi AH2, Hetete NM2, Alotibi NM3
1Ministry of Health, RIYADH, Saudi Arabia, 2King Salman Hospital, RIYADH, Saudi Arabia, 3Riyadh Health Affairs, MOH, RIYADH, Saudi Arabia

PHP112
C34
COST-EFFECTIVENESS THRESHOLD PROPOSAL FOR BOSNIA AND HERZEGOVINA
Catic T
ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia

PHP113
C35
INVESTIGATION ABOUT INFLUENCE OF MANAGEMENT STRATEGY IN NATIONAL HOSPITAL ORGANIZATION (NHO) HOSPITALS BY THE REVISION OF MEDICAL FEE SCHEDULE
Nakagawa Y1, Tomita N2, Irisa K1, Nakagawa Y1
1National Hospital Organization Shikoku Medical Center for Children and Adults, Zentuji city, Japan, 2National Institute of Public Health, Saitama, Japan

PHP114
C36
A SYSTEMATIC REVIEW OF ECONOMIC EVALUATION ALONGSIDE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPAN
Tran TT
University of Tsukuba, Tsukuba, Japan

PHP115
C37
ECONOMIC CONSEQUENCES OF THE CHOICES IN INJECTABLE ANTICOAGULANTS IN FRANCE
Paubel P1, Cousin M2, Amar C3, Gourmelen J4, Detournay B2
1General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 2Cemka-Eval, Bourg-la-Reine, France, 3ASPEN, Marly-le-roi, France, 4UMS 011 - Inserm - UVSQ, Villejuif, France

PHP116
C38
BIOSIMILARS: WHICH VALUE FOR SOCIETY?
Rémuzat C1, Kapuśniak A2, Lach S3, Dziwisz M3, Toumi M4
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Krakow, Poland, 3Creativ-Ceutical, Cracow, Poland, 4Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP117
D1
DOES HOSPITAL AT HOME NEED A NEW FUNDING FOR ORAL ANTI-CANCER DRUGS ?
Gohari A1, Mittaine-Marzac B1, Marquestaut O1, Paubel P2, Farinotti R1
1Hospital at Home, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 2General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

PHP118
D2
BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF BIOSIMILARS IN A BELGIAN TERTIARY CARE HOSPITAL: A SIMULATION
Claus BO1, Simoens S2, Vanhorebeek S3, Commeyne S3
1Ghent University, Ghent, Belgium, 2KU Leuven, Leuven, Belgium, 3Ghent University Hospital, Ghent, Belgium

PHP119
D3
ASSESSMENT OF PRICES OF ESSENTIAL MEDICINES FOR CHRONIC DISEASES PREVALENT IN THE ASIA PACIFIC REGION
Undela K
JSS College of Pharmacy, JSS University, Mysuru, India

PHP120
D4
IMPACT OF CHANGES IN THE METHODOLOGY OF EXTERNAL PRICE REFERENCING ON PRICES
Schneider P, Lepuschütz L, Zimmermann N, Vogler S
Gesundheit Österreich GmbH / Austrian Public Health Institute, Vienna, Austria

PHP121
D5
ECONOMIC BURDEN OF PRIMARY IMMUNODEFICIENCY IN NATIONAL INSTITUTE OF PEDIATRICS IN MEXICO
Maciel H
Universidad Nacional Autonoma de Mexico, Mexico City, Mexico

PHP122
D6
ASSESSMENT OF PRICE OF ESSENTIAL MEDICINES IN INDIA
Undela K
JSS College of Pharmacy, JSS University, Mysuru, India

PHP123
D7
THE IMPACT OF COST SHARING ARRANGEMENTS IN THE USE OF HEALTH CARE SERVICES DURING THE ECONOMIC CRISIS IN GREECE AND THE ATTITUDES OF CITIZENS
Kyriklidis K1, Kaitelidou D2, Angelopoulos G3, Samoutis A3, Konstantakopoulou O3, Siskou O3
1Istodierevnitiki S.A., Thessaloniki, Greece, 2Open University of Cyprus, Latsia, Nicosia, Cyprus, 3Center for Health Services Management and Evaluation, National and Kapodistrian University of Athens, Athens, Greece

PHP124
D8
OVERCOMING HTA HURDLES THROUGH EARLY COLLABORATION BETWEEN PHARMACEUTICAL COMPANIES AND COMPANION DIAGNOSTIC COMPANIES
Gambari J1, Senatore P2, Oshinowo B1, Armeni P3, Duttagupta S1, Chalmers M2
1CBPartners, New York, NY, USA, 2CBPartners, London, UK, 3Bocconi University, Milano, Italy

PHP125
D9
COST AVOIDANCE OF PHARMACIST RUNNING PEDIATRICS TOTAL PARENTERAL NUTRITION SERVICES AT MINISTRY OF HEALTH IN SAUDI ARABIA
Alomi YA1, Fallatah AO2
1Ministry of Health, RIYADH, Saudi Arabia, 2King Salman Hospital, RIYADH, Saudi Arabia

PHP126
D10
GENERIC DRUGS- DO THEY OFFER THE SAME SAFETY AND EFFICACY AS ORIGINATOR MEDICINES? -PERCEPTIONS AND ATTITUDES OF FINAL YEAR PHARMACY STUDENTS IN GREECE
Gkinou C1, Kani C2, Souliotis K2, Karalis V1, Markantonis S1
1National and Kapodistrian University of Athens, Athens, Greece, 2University of Peloponnese, Corinth, Greece

PHP127
D11
PRICES AND AFFORDABILITY OF REIMBURSED PHARMACEUTICALS: A EUROPEAN CROSS-COUNTRY STUDY
Walter E, Lazic-Peric A
Institute for Pharmaeconomic Research, Vienna, Austria

PHP128
D12
BIO-SIMILAR OR DIFFERENT? – UNDERSTANDING THE PAYER PERSPECTIVE
Kalbasko A, Spoors J
RJW & partners, Royson, UK

PHP129
D13
MEASURING OF THE UNCERTAINTY IN REIMBURSEMENT SYSTEM FOR MEDICINAL PRODUCTS
Araja D
Riga Stradins University, Riga, Latvia

PHP130
D14
CONCENTRATION ANALYSIS OF HUNGARIAN HEALTH CARE PROVIDERS BETWEEN 2006-2015
Csákvári T1, Turcsányi K1, Endrei D2, Sebestyén A3, Boncz I2
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary, 3National Health Insurance Fund Administration, Pécs, Hungary

PHP131
D15
ANALYZING THE REVENUES AND EXPENDITURES OF THE HUNGARIAN HEALTH INSURANCE FUND BETWEEN 1993-2015
Csákvári T1, Turcsányi K1, Endrei D2, Sebestyén A3, Boncz I2
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary, 3National Health Insurance Fund Administration, Pécs, Hungary

PHP132
D16
THE EVOLUTION OF PATIENT ACCESS SCHEMES
Spoors J1, Kusel J2
1RJW & Partners, Royston, UK, 2Costello Medical Consulting Ltd, Cambridge, UK

PHP133
D17
TAKING IN ACCOUNT RESEARCH AND DEVELOPMENT EXPENDITURES TO DETERMINE PRICES OF MEDICINES IN FRANCE: A REALISTIC ALTERNATIVE CHOICE?
Masia C, Nedellec E, Levy P
Université Paris-Dauphine, Paris, France

PHP134
D18
USE OF ELECTRONIC HEALTH INFORMATION SYSTEMS (EHIS) BY HEALTHCARE PROFESSIONALS (HCPS) AND THE PERCEPTION OF ITS VALUE IN REDUCING MEDICATION RISKS AND SAFETY FOR PATIENTS
Narayanan S1, Bullman WR2, Rucker NL3, Rausch P4
1Market Access Solutions, LLC, Potomac, MD, USA, 2NCPIE, Rockville, MD, USA, 3Enhance Value, Bethesda, MD, USA, 4Food and Drug Administration, Silver Spring, MD, USA

PHP135
D19
DATA REQUIREMENTS TO ENABLE INNOVATIVE PRICING APPROACHES
Santos S1, Botrugno P2, Dion K2
1Roche, Amadora, Portugal, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland

PHP136
D20
BIG DATA IN HEALTHCARE - OPPORTUNITIES AND CHALLENGES
Leppert F, Greiner W
School of Public Health, Bielefeld University, Bielefeld, Germany

PHP137
D21
PREDICTING LENGTH OF STAY AFTER ROAD TRAFFIC ACCIDENT ACCOUNTING FOR COMPETING ENDPOINTS WITH TIME-DEPENDENT VARIABLES
Van Belleghem G1, Devos S1, Lauwaert D2, Hubloue I2, Buyl R1, Pien K2, Putman K1
1Vrije Universiteit Brussel, Jette, Belgium, 2University hospital Brussel, Jette, Belgium

PHP138
D22
ASSESSMENT OF GENERAL KNOWLEDGE CONCERNING HEALTH-RELATED TOPICS
Zavras D, Kyriopoulos J
National School of Public Health, Athens, Greece

PHP139
D23
VALUE ADDED MEDICINES: THE NEED TO ESTABLISH ONE COMMON TERMINOLOGY FOR REPURPOSED MEDICINES
Rémuzat C1, Toumi M2
1Creativ-Ceutical, Paris, France, 2Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP140
D24
VALUE ADDED MEDICINES: WHAT VALUE REPURPOSED MEDICINES MIGHT BRING TO SOCIETY?
Rémuzat C1, Toumi M2
1Creativ-Ceutical, Paris, France, 2Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP141
D25
DO FIRST-IN-CLASS DRUGS OFFER LARGER INCREMENTAL HEALTH GAINS THAN NEXT-IN-CLASS DRUGS?
Chambers J1, Thorat T1, Wilkinson C1, Neumann PJ2
1Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA, 2Tufts University, Boston, MA, USA

PHP142
D26
TIME TO FORMAL ‎REIMBURSEMENT ‎FOR INNOVATIVE ‎DRUGS IN ITALY ‎
Eid MA1, Giuliani G2, Deroo V3
1University of Bologna, Bologna, Italy, 2Roche, Monza, Italy, 3Roche Spa, Monza, Italy

PHP143
D27
A STUDY EVALUATING LIVING ORGAN DONORS IN KIDNEY AND LIVER TRANSPLANTATION
Nair AG1, Noone JM2, Zacherle E1, Blanchette CM1
1University of North Carolina at Charlotte, Charlotte, NC, USA, 2Precision Health Economics, Davidson, NC, USA

PHP144
D28
COST-EFFICIENCY OF MEDICATION SAFETY PROGRAM AT PEDIATRICS, OBSTETRICS, AND GYNECOLOGY HOSPITAL, EAST PROVINCE, SAUDI ARABIA
Alomi YA1, Alanazi AA2, Alsallouk SA3, Almaznai MM3, Abu-Alnaja NI4, Alduhilan M4, Alhojelan B4
1Ministry of Health, RIYADH, Saudi Arabia, 2Maternity Children Hospital Dammam, Dammam, Saudi Arabia, 3Health Affairs Eastern Province, MOH, RIYADH, Saudi Arabia, 4Maternity Children Hospital Dammam, RIYADH, Saudi Arabia

PHP145
D29
PHARMACISTS MANPOWER ANALYSIS IN YEARS 2006-2014 AT MINSTERY OF HEALTH IN SAUDI ARABIA
Alomi YA, Alghamdi SJ, Alattyh RA
Ministry of Health, RIYADH, Saudi Arabia

PHP146
D30
ASSESSMENT OF CLINICAL AND ECONOMIC OUTCOMES OF PHARMACIST INTERVENTION IN TOTAL PARENTERAL NUTRITION PROGRAM IN SAUDI ARABIA
Alomi YA1, Fallatah AO2, Al-Smail EH2
1Ministry of Health, RIYADH, Saudi Arabia, 2King Salman Hospital, RIYADH, Saudi Arabia

PHP147
D31
CLINICAL AND ECONOMIC IMPACT OF PHARMACIST INTERVENTION AT CRITICAL CARE OF PRIVATE HOSPITAL IN RIYDAH, SAUDI ARABIA
Alomi YA1, El-Bahnasawi M2, Elemam AI2, Elgaili SH2, Kamran M2
1Ministry of Health, RIYADH, Saudi Arabia, 2Dr. Sulaiman Al-Habib Medical Group, RIYADH, Saudi Arabia

PHP148
D32
WORKLOAD ANALYSIS OF PARENTERAL NUTRITION SERVICES AT MINISTRY OF HEALTH HOSPITAL IN SAUDI ARABIA
Alomi YA1, Fallatah AO2, Al-Smail EH2
1Ministry of Health, RIYADH, Saudi Arabia, 2King Salman Hospital, RIYADH, Saudi Arabia

PHP149
D33
MANAGING EFFECTIVE ACCESS TO BIOSIMILARS: IN SEARCH OF AN OPTIMAL FRAMEWORK FOR CATALONIA
Gilabert-Perramon A1, Prat A2, Gil A3, Gimenez E3, Merino-Montero S3, Badia X3
1Catalan Health Service, Government of Catalonia, Barcelona, Spain, 2Servei Català de la Salut (CatSalut), Barcelona, Spain, 3Omakase Consulting, Barcelona, Spain

PHP150
D34
CLINICAL AND ECONOMIC OUTCOMES OF PHARMACIST INTERVENTION DURING THERAPEUTIC DRUG MONITORING PROGRAM IN SAUDI ARABIA
Alomi YA, Almudaiheem HY
Ministry of Health, RIYADH, Saudi Arabia

PHP151
D35
ADHERANCE TO MEDICATION ERRORS REPOTING SYSTEM AT PUBLIC HOSPITAL, RIYADH, SAUDI ARABIA
Alomi YA1, Al-Shubbar NA2
1Ministry of Health, RIYADH, Saudi Arabia, 2King Salman Hospital, RIYADH, Saudi Arabia

PHP152
D36
WORKLOAD ANALYSIS AND STAFFING REQUIREMENT OF CLINICAL PHARMACY SERVICES AT MINISTRY OF HEALTH IN SAUDI ARABIA
Alomi YA
Ministry of Health, RIYADH, Saudi Arabia

PHP153
D37
DIMENSIONALITY OF VALUE: ARE THE US AND EUROPE MOVING TOWARDS SIMILAR OR DIFFERENT DEFINITIONS OF PHARMACEUTICAL VALUE?
Capuano C1, Bower D1, Yampolsky D1, Curran K1, Suponcic S2
1Navigant Life Sciences, Boston, MA, USA, 2Navigant Life Sciences, Lawrenceville, NJ, USA

PHP154
D38
THE ETHICAL ISSUES OF PHARMACOGENETIC TESTS
Colak M, Tunceli HD, Pak MD
baskent university, Ankara, Turkey

PHP155
E1
STAKEHOLDERS VIEWS ON THE ROLE OF HTA AND RSAS IN PHARMACEUTICAL POLICY IN GREECE
Tsakalogiannis C, Karampli E, Athanasakis K, Kyriopoulos J
National School of Public Health, Athens, Greece

PHP156
E2
RECOMMENDATIONS IN CLINICAL GUIDELINES, ‘NO BENEFIT’ RATINGS, AND OPT-OUT DECISIONS IN GERMANY SINCE THE INTRODUCTION OF THE AMNOG LAW IN 2011: HOW DO THE PIECES FIT TOGETHER?
Staab TR1, Dintsios C2, Schulenburg J3, Ruof J1
1Roche Pharma, Grenzach-Wyhlen, Germany, 2Bayer Vital GmbH, Leverkusen, Germany, 3Leibniz University, Hanover, Germany

PHP157
E3
GENERAL PRACTITIONERS AWARENESS ON MEDICINES COST AND FINANCING IN BOSNIA AND HERZEGOVINA
Catic T1, Martinovic I2, Avdagic L3
1ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia, 2Bosnalijek JSC, Sarajevo, Bosnia and Herzegovina, 3Faculty of Economics, Sarajevo, Bosnia and Herzegovina

PHP158
E4
ACCESS TO NEW DRUGS AFTER THE INTRODUCTION OF THE 2011 REIMBURSEMENT ACT IN POLAND
Zaremba A, Iwanczuk T, Tatara T, Misiak J, Krakowian P, Wysoczanski W
Agency for Health Technology Assessment and Tariff System in Poland (AOTMiT), Warsaw, Poland

PHP159
E5
IMPLEMENTATION OF THE INSURANCE PROGRAMS FOR CATASTROPHIC DISEASES IN CHINA: A QUALITATIVE STUDY
MAO W, Chen W
Fudan University, Shanghai, China

PHP160
E6
PHARMACEUTICAL REIMBURSEMENT OF INNOVATIVE MEDICINAL PRODUCTS IN BELGIUM
Van Wilder P, Bormans V
SMART&BI, Zaventem, Belgium

PHP161
E7
LINEAR, FLAT AND MIXED PRICING STRUCTURES AS NEGOTIATION QUANTITIES OF NEW MEDICINAL PRODUCTS IN CONTEXT OF AMNOG IN GERMANY: A COMPARISON AT MARKET LAUNCH AND POST PRICE NEGOTIATIONS
Bot D, Campion M, Ecker T
Ecker + Ecker GmbH, Hamburg, Germany

PHP162
E8
MARKET UPTAKE OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN GERMANY
Batscheider A1, Greese B1, Dannemann S1, Gaba D2, Paulus G1, Antoni B1, Stoecker P1, Peters A1, Greiner R1
1QuintilesIMS, Munich, Germany, 2QuintilesIMS, Gurgaon, India

PHP163
E9
THE NORMAL REIMBURSEMENT PROCEDURE OF THE PHARMACEUTICAL SUBMISSIONS BETWEEN 2013 AND 2015 IN HUNGARY - NEEDS AND RESULTS
Csordás A, Lőrincz O, Éder B
National Institute of Pharmacy and Nutrition, Budapest, Hungary

PHP164
E10
BIOSIMILARS AND REFERENCE PRICE GROUPS IN GERMANY
Eheberg D1, Pointner J2, Antoni B3, Gossmann JA2, Batscheider A4
1IMS Health, Munich, Germany, 2IMS Health Germany, Munich, Germany, 3QuintilesIMS, Munich, Germany, Munich, Germany, 4QuintilesIMS, Munich, Germany

PHP165
E11
EXTRA BUDGETARY REIMBURSEMENT OPTIONS FOR INNOVATIONS IN THE GERMAN HOSPITAL SECTOR
Freiberg M, Schwarz R, Schalk E, Kraft T
Quintiles Commercial Germany GmbH, Mannheim, Germany

PHP166
E12
REDUCING MEDICAL CLAIMS COST TO GHANA’S NATIONAL HEALTH INSURANCE SCHEME: PAPER-BASED VERSUS ELECTRONIC-BASED CLAIMS REVIEW
Nsiah-Boateng E
National Health Insurance Authority, Accra, Ghana

PHP167
E13
THE ROLE AND IMPACT OF EVIDENCE REVIEW GROUP ANALYSES IN THE NICE SINGLE TECHNOLOGY ASSESSMENT (STA) PROCESS
Carroll C1, Kaltenthaler E1, Tappenden P1, Hill-McManus D2, Scope A1, Holmes M1, Rice S3, Rose M4, Woolacott N5
1University of Sheffield, Sheffield, UK, 2Bangor University, Bangor, UK, 3Newcastle University, Newcastle upon Tyne, UK, 4Southampton University, Southampton, UK, 5University of York, York, UK

PHP168
E14
EARLY MARKET ACCESS FOR PHARMACEUTICALS IN EU: WHAT IS THE IMPACT OF EMA’S ACCELERATED ASSESSMENT PROCEDURE?
Haijeji B1, Belgaied W1, Sediri Y1, Parviainen L2, Rémuzat C3, Toumi M4
1Creativ-Ceutical, Tunis, Tunisia, 2Creativ-Ceuticals, Rotterdam, The Netherlands, 3Creativ-Ceuticals, Paris, France, 4Aix-Marseille University, Marseille, France

PHP169
E15
WITHDRAWN

PHP170
E16
MARKET ACCESS PATHWAYS FOR DRUGS WITH EMA CONDITIONAL APPROVAL
Lie X1, Kreeftmeijer J1, Bossers N1, Haigh J2
1Quintiles Advisory Services, Hoofddorp, The Netherlands, 2Quintiles Advisory Services, Reading, UK

PHP171
E17
THE ROAD TO RUSSIAN PHARMACOECONOMICS: UNDERSTANDING THE DRIVERS FOR ACCESS TO HIGH-VALUE / ORPHAN DISEASE DRUGS
Subbotina E1, Chowdhury CA2
1CBPartners, London, UK, 2CBPartners, New York, NY, USA

PHP172
E18
RETROSPECTIVE REVIEW OF OBSERVATIONAL DATA REQUESTED BY THE FRENCH HEALTH AND TECHNOLOGY ASSESSMENT AGENCY: HOW ARE RESULTS TAKEN INTO ACCOUNT?
Fernandez J, Pinet M, Taransaud J, d'Andon A
French National Authority for Health (HAS), Saint Denis La Plaine, France

PHP173
E19
THE VALUE OF MCDA IN HEALTH TECHNOLOGY ASSESSMENT: A EXPLORATIVE STUDY IN THE DUTCH CONTEXT
van Til JA1, Groothuis-Oudshoorn CG2, Baltussen R3, Zwaap J4, Boer B5, IJzerman MJ2
1University of Twente, Enschede, The Netherlands, 2MIRA institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands, 3Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands, 4Zorginstituut Nederland, Diemen, The Netherlands, 5Erasmus University Rotterdam, Rotterdam, The Netherlands

PHP174
E20
VARIATIONS IN STAKEHOLDER PREFERENCES BETWEEN INNOVATIVE PRICING AGREEMENT TYPES ACROSS THE EU5
Edwards G1, Staufer A2, Dunlop W3
1IMS Consulting Group, Cambridge, UK, 2Mundipharma International Limited, Cambridge, UK, 3Mundipharma International Ltd, Cambridge, UK

HEALTH CARE USE & POLICY STUDIES - Health Care Research & Education
PHP175
E21
SIMULATING PATIENT-LEVEL PROFILES TO CAPTURE PATIENT HETEROGENEITY IN HEALTH-ECONOMIC APPLICATIONS
Rael M1, Ishak J2
1Evidera, San Francisco, CA, USA, 2Evidera, Montreal, QC, Canada

PHP176
E22
QUANTIFICATION OF PATIENT PREFERENCE ANALYSIS: WEARING THE FEDERAL JOINT COMMITTEE LENS TO ASSESS EVIDENCE
Gaba D1, Eheberg D2, Bonduelle D2
1QuintilesIMS, Gurgaon, India, 2IMS Health, Munich, Germany

PHP177
E23
PSYCHOMETRIC TESTING OF THE FINNISH VERSION OF THE PROSTHESIS EVALUATION QUESTIONNAIRE
Repo JP1, Piitulainen K2, Tukiainen EJ1, Roine RP3, Kautiainen H3, Becker P4, Häkkinen A5
1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2University of Jyvaskyla, Jyvaskyla, Finland, 3Helsinki and Uusimaa Hospital District, Helsinki, Finland, 4University of Jyväskylä, Jyväskylä, Finland, 5University of Jyvaskylä, Jyvaskylä, Finland

PHP178
E24
EPIDEMIOLOGICAL CHARACTERISTICS OF HOSPITALIZATIONS DUE TO ADVERSE DRUG REACTIONS (ADRS) RELAED TO ORAL ANTICOAGULANTS IN SPAIN: 2010-2013
Carrasco-Garrido P1, Lopez De Andres A1, Hernandez Barrera V1, Esteban-Hernandez J1, Jimenez-Trujillo I1, Alvaro-Meca A1, Muñoz Robles JA2, Rodriguez JM3, Jimenez-Garcia R1
1Rey Juan Carlos University, Alcorcon (MADRID), Spain, 2Daiichi Sankyo Iberia, MADRID, Spain, 3Daiichi Sankyo Europe GmbH, Munich, Germany

PHP179
E25
EVOLUTIONS IN THE PEER-REVIEW PUBLICATION LANDSCAPE AND THEIR IMPLICATIONS FOR SYSTEMATIC LITERATURE REVIEWS
Adkins E, Cadwell K, Pooley N, Fox D, Floyd D
PHMR Ltd, London, UK

PHP180
E26
MCDA APPLICATION IN CENTRAL AND EASTERN EUROPE: SELECTION OF THE MOST IMPORTANT CRITERIA BASED ON EXAMPLES
Nemeth B1, Piniazhko O2
1Syreon Research Institute, Budapest, Hungary, 2Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

PHP181
E27
A CROSS-NATIONAL COMPARISON OF THE EFFECT OF AGE AND GENDER ON HEALTH-RELATED QUALITY OF LIFE (HRQL)
Rendas-Baum R1, White MK1, Kosinski M1, Vietri J2, Bjorner JB1
1Optum, Lincoln, RI, USA, 2Kantar Health, Horsham, PA, USA

PHP182
E28
EQ-5D STUDIES IN NERVOUS SYSTEM DISEASES IN EIGHT CENTRAL AND EASTERN EUROPEAN COUNTRIES
Prevolnik Rupel V1, Turk E2, Péntek M3, Rencz F3, Golicki D4, Simon J5, Brodszky V3, Baji P3, Zrubka Z3, Zavada J6, Petrova G7, Rotar A8, Gulacsi L3
1Institute for Economic Research, Ljubljana, Slovenia, 2DNV GL, Hovik, Norway, 3Corvinus University of Budapest, Budapest, Hungary, 4Department of Experimental & Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland, 5Medical University of Vienna, Vienna, Austria, 6Institute of Rheumatology, Prague, Czech Republic, 7Medical University Sofia, Faculty of Pharmacy, and President, ISPOR Bulgaria Chapter, Sofia, Bulgaria, 8University of Amsterdam, Amsterdam, The Netherlands

PHP183
E29
HOW TO SELECT THE BEST COMPARATOR? AN INTERNATIONAL ECONOMIC EVALUATION GUIDELINES COMPARISON
Ziouani S1, Granados D2, Borget I1
1Univ Paris-Sud, Faculty of Pharmacy, GRADES, Châtenay-Malabry, France, 2Janssen, Issy-les-Moulineaux, France

PHP184
E30
HEALTH-RELATED QUALITY OF LIFE (HRQOL) BASED ON PREFERENCES FROM 14 COUNTRIES IN PRIMARY HEALTH CARE SETTING (PHCS)
Soini EJ1, Heinonen J2, Miettola E2, Ryynänen O3, Koskela T4
1ESIOR Oy, Kuopio, Finland, 2School of Medicine, University of Tampere, Finland, 3Faculty of Health Sciences, University of Eastern Finland, and Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, 4Department of General Practice, University of Tampere, and Omapihlaja, Pihlajalinna Terveys Oy, Tampere, Finland

PHP185
E31
PREFERENCES FOR THE CHARACTERISTICS OF HOME ENTERAL NUTRITION (HEN) VIA TUBE FEEDING: A DISCRETE-CHOICE EXPERIMENT
Olveira G1, Martinez-Olmos MA2, Fernandez de Bobadilla B3, Ferrer M4, Virgili N5, Vega B6, Blanco M7, Layola M7, Lizan L8, Tribaldos de Suarez M9
1Hospital Regional Universitario de Málaga, Malaga, Spain, 2Hospital Universitario de Santiago, Santiago de Compostela, Spain, 3Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, 4Hospital Clínico Universitario Virgen de Arrixaca de Murcia, Murcia, Spain, 5Hospital Bellvitge, Barcelona, Spain, 6Hospital Universitario Ramón y Cajal, Madrid, Spain, 7Nestle health science, Barcelona, Spain, 8Outcomes 10, Universitat Jaume I, Castellon, Spain, 9Outcomes 10, Castellon, Spain

PHP186
E32
HOW TO DEFINE RELEVANT COMPARATORS IN FRANCE? AN ANALYSIS OF THE ECONOMIC EVALUATIONS SUBMITTED BY MANUFACTURERS AND REVIEWED BY THE ECONOMIC COMMITTEE (CEESP) OF THE FRENCH NATIONAL HEALTH AUTHORITY
Ziouani S1, Granados D2, Benjamin L2, Borget I1
1Univ Paris-Sud, Faculty of Pharmacy, GRADES, Châtenay-Malabry, France, 2Janssen, Issy-les-Moulineaux, France

PHP187
E33
LIFESTYLE BELIEFS OF 672 PATIENTS WITH RHEUMATOID ARTHRITIS OR AXIAL SPONDYLOARTHRITIS
Gossec L1, Cukierman G2, Saraux A3, Chauvin P4, Poussière M5, Saulot V6, Russo-Marie F6, Joubert J2, Hudry C7, Berenbaum F8
1Paris 06 University, Paris, France; AP-HP, Hôpital Pitié Salpêtrière, Paris, France, 2UCB Pharma, Colombes, France, 3CHU La Cavale Blanche and Université de Bretagne Occidentale, Brest, France, 4Paris 06 University, Paris, France; INSERM, Paris, France, 5Independent Researcher, Paris, France, 6Arthritis Fondation Courtin, Neuilly-sur-Seine, France, 7AP-HP Hôpital Cochin, Paris, France, 8Paris 06 University, Paris, France; INSERM, Paris, France; AP-HP, Hôpital Saint-Antoine, Paris, France

PHP188
E34
PSYCHOMETRIC PROPERTIES OF THE FINNISH VERSION OF THE LOCOMOTOR CAPABILITIES INDEX-5
Becker P1, Repo JP2, Piitulainen K1, Tukiainen EJ2, Roine RP3, Järvenpää S1, Ylinen J4, Häkkinen A5
1University of Jyväskylä, Jyväskylä, Finland, 2University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 3Helsinki and Uusimaa Hospital District, Helsinki, Finland, 4Central Finland Central Hospital, Jyväskylä, Finland, 5University of Jyvaskyla, Jyvaskyla, Finland

PHP189
E35
ARE ALLOCATION PREFERENCES IN HEALTH CARE CONSISTENT WITH A PARTICULAR DEFINITION OF SEVERITY? RESULTS FROM A RANDOM-SAMPLE SURVEY OF NORWEGIANS
Østby JT1, Desser AS2, Kristiansen IS3
1Pfizer Norway, Oslo, Norway, 2Norwegian Institute of Public Health, Oslo, Norway, 3University of Oslo, Oslo, Norway

PHP190
E36
PROMPT VALUE ASSESSMENT OF BREAKTHROUGH INTERVENTIONS WITH LIMITED OUTCOME DATA
Arbel R1, Hammerman A2, Triki N3, Greenberg D4
1Sapir College, Sderot, Israel, 2Clalit Health Services, Tel-Aviv, Israel, 3Maccabi Healthcare Services, Tel-Aviv, Israel, 4Ben-Gurion University of the Negev, Beer-Sheva, Israel

PHP191
E37
DIRECTLY ELICITING PERSONAL UTILITY FUNCTIONS FROM A CONVENIENCE SAMPLE OF 30 HEALTH OUTCOMES PROFESSIONALS: A PILOT STUDY
Pantiri K1, Shah K2, Devlin N2, Mulhern B3, van Hout B4
1Pharmerit BV, Rotterdam, The Netherlands, 2Office of Health Economics, London, UK, 3University of Technology Sydney, Sydney, Australia, 4University of Sheffield, Sheffield, UK

PHP192
E38
INNOVATIVE MEDICAL DEVICE DESIGN SIGNIFICANTLY REDUCES SURGEON INTRA-PROCEDURAL STRESS LEVELS (IPSL)
MacDonald M, Lombard J, Sutton N, Hinoul P, Ilie B
Johnson & Johnson Medical Devices, Somerville, NJ, USA

PHP193
WITHDRAWN

PHP194
F1
HIGH LEVELS OF FEARS OF PATIENTS WITH RHEUMATOID ARTHRITIS OR AXIAL SPONDYLOARTHRITIS ARE ASSOCIATED WITH GENDER, DISEASE ACTIVITY, ANXIETY AND DEPRESSION: A CROSS-SECTIONAL STUDY OF 672 PATIENTS
Gossec L1, Cukierman G2, Chauvin P3, Hudry C4, Poussière M5, Saulot V6, Russo-Marie F6, Joubert J2, Saraux A7, Berenbaum F8
1Paris 06 University, Paris, France; AP-HP, Hôpital Pitié Salpêtrière, Paris, France, 2UCB Pharma, Colombes, France, 3Paris 06 University, Paris, France; INSERM, Paris, France, 4AP-HP Hôpital Cochin, Paris, France, 5Independent Researcher, Paris, France, 6Arthritis Fondation Courtin, Neuilly-sur-Seine, France, 7CHU La Cavale Blanche and Université de Bretagne Occidentale, Brest, France, 8Paris 06 University, Paris, France; INSERM, Paris, France; AP-HP, Hôpital Saint-Antoine, Paris, France

PHP195
F2
PSYCHOMETRIC PROPERTIES OF THE FINNISH VERSION OF THE LOWER EXTREMITY FUNCTIONAL SCALE AMONG FOOT AND ANKLE PATIENTS
Repo JP1, Tukiainen EJ1, Roine RP2, Ilves O3, Jarvenpää S3, Häkkinen A3
1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Helsinki and Uusimaa Hospital District, Helsinki, Finland, 3University of Jyvaskyla, Jyvaskyla, Finland

PHP196
F3
A REAL CONCERN OR JUST A HYPE? – EVIDENCE ON NEGATIVE CLINICAL CONSEQUENCES OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR BASED ON A SYSTEMATIC LITERATURE REVIEW
Inotai A1, Prins CP2, Csanadi M1, Szegner P3, Vitezic D4, Kaló Z5
1Syreon Research Institute, Budapest, Hungary, 2Utrecht University, Department of Pharmaceutical Sciences, Utrecht, The Netherlands, 3Eötvös Loránd University, Budapest, Hungary, 4University of Rijeka, School of Medicine and University Hospital Centre Rijeka, Rijeka, Croatia, 5Eötvös Loránd University (ELTE), Budapest, Hungary

PHP197
F4
THE INVARIANCE ANALYSIS OF SF12V2: ¿ARE COMPARABLE THE QUALITY OF LIFE RESULTS OF MEN AND WOMEN?
Pedrero V1, Oyarte M1, Espinoza MA2
1Universidad del Desarrollo, Santiago, Chile, 2Pontificia Universidad Catolica de Chile, Santiago, Chile

PHP198
F5
COMPARISON OF WEB-BASED SIGNAL DETECTION USING MEDICAL FORUMS DATA IN FRANCE FROM 2005-2015 WITH SIGNALS FROM VIGIBASE®
Schück S1, Kürzinger M2, Abdellaoui R1, Texier N1, Pouget J3, Faviez C1, Zhang L4, Tcherny-Lessenot S2, Juhaeri J4, Welsh S4
1Kappa Santé, Paris, France, 2Global Pharmacovigilance and Epidemiology, Sanofi, Chilly-Mazarin, France, 3Information Technology Solutions, Sanofi, Lyon, France, 4Global Pharmacovigilance and Epidemiology, Sanofi, Bridgewater, NJ, USA

PHP199
F6
IMPACT OF BURDENSOME CHRONIC CONDITIONS ON HEALTH-RELATED QUALITY OF LIFE AMONG EUROPEANS: ANALYSIS OF EQ-5D-5L VAS SCORES
Dreyfus J1, Vietri J2
1Kantar Health, Paris, France, 2Kantar Health, Horsham, PA, USA

PHP200
F7
DEVELOPMENT OF DAY SURGERY IN HUNGARY BETWEEN 2004-2014
Gresz M1, Endrei D2, Csákvári T3, Danku N2, Sebestyén A4, Horváth L2, Boncz I2
1National Healthcare Service Center, Budapest, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pécs, Zalaegerszeg, Hungary, 4National Health Insurance Fund Administration, Pécs, Hungary

PHP201
F8
THE PROBABILISTIC EFFICIENCY FRONTIER: A VALUE ASSESSMENT OF TREATMENT OPTIONS IN HEPATITIS C
Mühlbacher A, Sadler A
Hochschule Neubrandenburg, Neubrandenburg, Germany

PHP202
F9
ESTIMATION OF VALUE OF LIFE WITH A MODEL APPROACH DEPENDING ON NET PRESENT VALUE FOR FRANCE, GERMANY, ITALY, SPAIN AND UNITED KINGDOM
Tuna E1, Yenilmez FB2, Kockaya G3
1Polar Health Economics and Policy Consultancy, Ankara, Turkey, 2Hacettepe University, Ankara, Turkey, 3Health Economics and Policy Association, Ankara, Turkey

PHP203
F10
THE REDUCTION OF CEILING WITH THE EQ-5D-5L INCREASES WITH AGE IN THE GENERAL ADULT POPULATION
Scalone L1, Ciampichini R1, Cesana G1, Cortesi PA1, Janssen B2, Mantovani LG1
1University of Milano-Bicocca, Monza, Italy, 2EuroQol Research Foundation, Rotterdam, The Netherlands

PHP204
F11
JOB BURNOUT PREDICTORS IN COMMUNITY PHARMACISTS IN SERBIA
Jocic DD1, Krajnovic DM2, Lakic DM2
1BENU, Belgrade, Serbia, 2Faculty of Pharmacy - University of Belgrade, Belgrade, Serbia

PHP205
F12
THE USE OF PHARMACOECONOMIC EVIDENCE TO ENCOURAGE GENERIC MEDICINES USE IN JORDAN: A COST MINIMIZATION ANALYSIS
El-Dahiyat F
The Hashemite University, Zarqa, Jordan

PHP206
F13
IS THE INSTITUTE OF CLINICAL AND ECONOMIC REVIEW (ICER) SET UP FOR SUCCESS? A COMPARISON BETWEEN ICER AND EX-U.S. HTA AGENCIES
Skolas K1, Pruefert A1, Yee S2, van Engen A3
1Quintiles Advisory Services, Cambridge, MA, USA, 2Quintiles Advisory Services, New York, NY, USA, 3Quintiles Advisory Services, Hoofddorp, The Netherlands

PHP207
WITHDRAWN

PHP208
F14
RELATIONSHIP BETWEEN ORPHAN DISEASE PREVALENCE, DIFFERENTIAL HTA VALUE ASSESSMENT, AND ORPHAN DRUG PRICING IN SEVEN EUROPEAN COUNTRIES
Sladeček S1, Cockerill K1, Hegde S2, Funderburk A2, Graeve C1, Gaebler JA2
1Health Advances GmbH, Zug, Switzerland, 2Health Advances LLC, Weston, MA, USA

PHP209
F15
THE NUMBER OF CASES IN PHYSIOTHERAPY SERVICES WITHIN SPECIALIZED HOME CARE IN HUNGARY BETWEEN 2010 AND 2014
Molics B1, Hanzel A1, Juhász K2, Sebestyén A2, Gyuró M1, Endrei D1, Boncz I1
1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Pécs, Hungary

PHP210
F16
THE UTILIZATION OF SELECTED SCREENING TESTS IN GREECE: A DESCRIPTIVE ANALYSIS
Naoum P1, Mavrikou M1, Charonis A1, Balasopoulos T1, Kyriopoulos I2, Karokis A3, Athanasakis K1, Pavi E1, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2London School of Economics and Political Science, London, UK, 3MSD Greece, Athens, Greece

PHP211
F17
LINGUISTIC VALIDATION OF THE FINNISH VERSION OF THE VISUAL ANALOGUE SCALE FOOT AND ANKLE INSTRUMENT
Repo JP1, Tukiainen EJ1, Ilves O2, Häkkinen A2
1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2University of Jyvaskyla, Jyvaskyla, Finland

PHP212
F18
EARLY PAYER SCIENTIFIC ADVICE PROCEDURES IN THE EU: WHICH ONE IS MOST SUITED FOR PHARMACEUTICAL COMPAINES?
Wolfram V1, Bailey S1, Foxon G1, Craddy P2
1Remap Consulting, Cheshire, UK, 2Remap Consulting, Zug, Switzerland

PHP213
F19
COMPARING EQ-5D-3L AND EQ-5D-5L IN A GENERAL POPULATION
Ferreira LN1, Ferreira PL2, Pereira LN3, Antunes P2
1Universidade do Algarve, Faro, Portugal, 2CEISUC, Coimbra, Portugal, 3Research Centre for Spatial and Organizational Dynamics (CIEO), Faro, Portugal

PHP214
F20
VALIDATION OF COMORBIDITY INDICES (CHARLSON AND ELIXHAUSER) COMPUTED IN CROSS SECTIONAL HOSPITAL BILLING DATA
Wei D1, Narain A1, Lerner J2, Yoo A1, Kalsekar I3
1Epidemiology & Health Informatics, Medical Devices, Johnson and Johnson Co., New Brunswick, NJ, USA, 2DePuy Synthes, Inc., Raynham, MA, USA, 3Johnson & Johnson Co., New Brunswick, NJ, USA

PHP215
F21
ESTIMATION OF VALUE OF LIFE WITH A MODEL APPROACH DEPENDING ON NET PRESENT VALUE FOR TURKEY
Kockaya G1, Yenilmez FB2, Tuna E3
1Health Economics and Policy Association, Ankara, Turkey, 2Hacettepe University, Ankara, Turkey, 3Polar Health Economics and Policy Consultancy, Ankara, Turkey

PHP216
F22
PARTICIPATION OF EXTERNAL MEDICAL SOCIETIES IN THE BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY
Bleß H, de Millas C, Kern B
IGES Institut GmbH, Berlin, Germany

PHP217
F23
PATIENTS' ACCEPTANCE AND ADHERENCE OF THEIR MEDICATION: RESULTS FROM A EUROPEAN MULTI-DISEASE STUDY WITH ONLINE PATIENT COMMUNITY
de Bock E1, Chekroun M2, Morisky DE3, Arnould B4
1Mapi Group, Patient-Centered Outcomes, Lyon, France, 2carenity.com, Paris, France, 3UCLA Fielding School of Public Health, Los Angeles, CA, USA, 4Mapi Group, Lyon, France

PHP218
F24
ASSESSING QUALITY OF LIFE OF SELF-REPORTED RHEUMATIC PATIENTS
Ferreira LN1, Ferreira PL2, Pereira LN3, Antunes P1, Gonçalves S4, Gouveia N4, Rodrigues A4, Canhao H4, Branco JC4
1CEISUC, Coimbra, Portugal, 2Faculty of Economics, Coimbra, Portugal, 3Research Centre for Spatial and Organizational Dynamics (CIEO), Faro, Portugal, 4Sociedade Portuguesa de Reumatologia, Lisbon, Portugal

PHP219
F25
ITALIAN ELECTRONIC HEALTH RECORDS MAPPING: IS CLINICAL DATA COLLECTION GETTING IN LINE WITH THE REAL WORLD EVIDENCE ERA?
Avitabile A1, Caputo A1, Gilardelli G1, Golotta C1, La Grasta L1, Heiman F2, Porrello N1
1Roche S.p.A., Monza, Italy, 2IMS Health Information Solutions Italy S.r.l., Milan, Italy

PHP220
F26
DIFFERENTIATION OF HEALTH RELATED QUALITY OF LIFE OUTCOMES BETWEEN PATIENT POPULATIONS; RESULTS FROM PATIENTS WITH BREAST CANCER, RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, RARE CANCERS AND RARE DISEASES
Efthymiadou O1, Kanavos P1, Mossman J2
1London School of Economics and Political Science, London, UK, 2European Brain Council, Brusells, Belgium

PHP221
F27
ASSESSMENT OF PATIENT NEED DURING HOSPITALIZATION BY USING NEQ (NEED EVALUATION QUESTIONNAIRE) IN TERTIARY CARE HOSPITALS, QUETTA, PAKISTAN
Nasim A, Haq N, Rehmat S, Riaz S, Aziz MF
University of Balochistan, Quetta, Pakistan

PHP222
F28
ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS) IN EUROPE 8 YEARS ON: WHAT IS THE PATH TO MARKET ACCESS SO FAR?
Mycka J1, Dellamano R2, Lobb W1, Dalal N1, Dellamano L2
1Medical Marketing Economics LLC (MME), Montclair, NJ, USA, 2ValueVector, Milan, Italy

PHP223
F29
BUDGET IMPACT MODEL – GLOBAL NEEDS TO GO LOCAL
Wang-Silvanto J, Buckland A, Hirst A, Shephard C, Vlachaki I
WG Access Ltd, London, UK

PHP224
F30
ESTIMATION OF VALUE OF LIFE WITH A MODEL APPROACH DEPENDING ON NET PRESENT VALUE FOR AUSTRIA, CANADA, JAPAN AND USA
Yenilmez FB1, Tuna E2, Kockaya G3
1Hacettepe University, Ankara, Turkey, 2Polar Health Economics and Policy Consultancy, Ankara, Turkey, 3Health Economics and Policy Association, Ankara, Turkey

PHP225
F31
RAPID, COMPREHENSIVE ORAL NUTRITIONAL SUPPLEMENT QUALITY IMPROVEMENT PROGRAM REDUCES LENGTH OF STAY IN MALNOURISHED HOSPITALIZED PATIENTS
Summerfelt WT1, Sulo S2, Partridge J2, VanDerBosch G1, Hegazi R2, Sriram K1
1Advocate Health Care, Downers Grove, IL, USA, 2Abbott Nutrition, Columbus, OH, USA

PHP226
F32
COMORBIDITY-BASED EQ-5D SCORES OF PRIMARY CARE PATIENTS IN FINLAND, THEIR POTENTIAL TO BENEFIT AND UNMET MEDICAL NEED
Soini EJ1, Heinonen J2, Miettola E2, Ryynänen O3, Koskela T4
1ESIOR Oy, Kuopio, Finland, 2School of Medicine, University of Tampere, Finland, 3Faculty of Health Sciences, University of Eastern Finland, and Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, 4Department of General Practice, University of Tampere, and Omapihlaja, Pihlajalinna Terveys Oy, Tampere, Finland

PHP227
F33
INFLUENCING FACTORS ON KNOWLEDGE, ATTITUDE AND BEHAVIOUR TOWARDS ANTIBIOTIC USAGE AMONG ADULTS IN HO CHI MINH CITY, VIET NAM
Ngo TN1, Tran MK2, Nguyen TT3
1University of medcine and pharmacy, Ho Chi Minh City, Ho Chi Minh, Viet Nam, 2University of medicine and pharmacy, HCMC, Ho chi minh, Viet Nam, 3University of medicine and pharmacy, Ho Chi Minh City, Ho Chi Minh City, Viet Nam

PHP228
F34
ESTIMATING STUDY COSTS FOR USE IN VOI, A STUDY OF DUTCH PUBLICLY FUNDED DRUG RELATED RESEARCH
van Asselt AD1, Ramaekers BL2, Corro Ramos I3, Joore MA4, Al MJ5, Lesman-Leegte I1, Postma MJ6, Vemer P6, Feenstra TF1
1University Medical Center Groningen, Groningen, The Netherlands, 2Maastricht University Medical Center+, Maastricht, The Netherlands, 3Erasmus University, Rotterdam, The Netherlands, 4Maastricht University Medical Center, Maastricht University, Maastricht, The Netherlands, 5Erasmus University Rotterdam, Rotterdam, The Netherlands, 6University of Groningen, Groningen, The Netherlands

PHP229
F35
SHOULD PATIENTS ESTIMATE HEALTH RELATED QUALITY OF LIFE? THE RESULTS OF EMPIRICAL STUDY
Prevolnik Rupel V, Ogorevc Marko M
Institute for Economic Research, Ljubljana, Slovenia

PHP230
F36
RECONSTRUCTION OF MAJOR LOWER-EXTREMITY AMPUTATION STUMP WITH A FREE LATISSIMUS DORSI FLAP
Repo JP1, Roine RP2, Sintonen H3, Tukiainen EJ1
1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Helsinki and Uusimaa Hospital District, Helsinki, Finland, 3University of Helsinki, Helsinki, Finland

PHP231
F37
EXTENSION OF THE LABELS WITHIN THE EQ-5D-Y
Kreimeier S1, Åström M2, Burström K2, Egmar A3, Gusi N4, Herdman M5, Kind P6, Oppe M7, Pérez Sousa M4, Greiner W8
1University of Bielefeld, Bielefeld, Germany, 2Karolinska Institutet Stockholm, Stockholm, Sweden, 3The Swedish Red Cross University College Stockholm, Stockholm, Sweden, 4University of Extremadura, Caceres, Spain, 5Insight Consulting and Research, Barcelona, Spain, 6HSE University, St. Petersburg, Russia, 7EuroQol Research Foundation, Rotterdam, The Netherlands, 8School of Public Health, Bielefeld University, Bielefeld, Germany

PHP232
F38
INVESTIGATION OF THE WORK ABILITY OF NURSES AND ITS INFLUENCING FACTORS
Pocsai N1, Danku N2, Boncz I2, Horváthné Kívés Z2
1Vasútegészségügyi NK Kft Szegedi Egészségügyi Központ, Szeged, Hungary, 2University of Pécs, Pécs, Hungary

PHP233
G1
EVALUATION OF THE IMPACT OF PHARMACISTS QUALIFICATION AND YEARS OF PRACTICE ON PHARMACEUTICAL CARE SERVICES IN COMMUNITY PHARMACY PRACTICE IN ENUGU NIGERIA
Ogbonna B
NNAMDI AZIKIWE UNIVERSITY, AWKA, Nigeria

PHP234
G2
RECENT TRENDS IN DIFFERENT DEVICES, OPERATING SYSTEMS, AND BROWSERS USED BY PATIENTS TAKING PART IN ONLINE MEDICAL SURVEYS
Wade AG, Crawford GM, McLennan K
Patients Direct, Glasgow, UK

PHP235
G3
CLINICAL TRIALS SCENARIO IN BRAZIL: STUDY AND SPONSOR PROFILES
Julian G1, Moreira Ed1, de Oliveira RW1, Francisco Fd2, Ruenis AP2
1Evidências - Kantar Health, São Paulo, Brazil, 2ABRACRO, São Paulo, Brazil

PHP236
G4
COMPARATIVE ANALYSIS OF MEDICATION POSSESSION RATIO MEASURES FOR ADHERENCE TO SINGLE-MEDICATION
Ágh T
Syreon Research Institute, Budapest, Hungary

PHP237
G5
GOOD ENOUGH FOR POLICY WORK? STUDY-DESIGN CHALLENGES IN IMPLEMENTING STATED-PREFERENCE METHODS FOR COMPLEX HEALTH-CARE TECHNOLOGIES
Marshall DA1, Gonzalez JM2, MacDonald KV3, Johnson FR4
1Alberta Bone and Joint Health Institute, Calgary, AB, Canada, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3University of Calgary, Calgary, AB, Canada, 4Duke Clinical Research Institute, Durham, NC, USA

PHP238
G6
HAVE BUDGET IMPACT ANALYSES INCLUDED CLINICAL OUTCOMES?
Wang-Silvanto J1, Taylor M2, Buckland A1, Hirst A1, Shephard C1, Vlachaki I1
1WG Access Ltd, London, UK, 2York Health Economics Consortium, Heslington, York, UK

PHP239
G7
UTILIZATION OF PHYSIOTHERAPY VISITS COMPLETED IN SPECIALIZED HOME CARE IN HUNGARY BETWEEN 2010 AND 2014
Molics B1, Simon-Ugron Á2, Mihajlovic I3, Gyuró M1, Ács P1, Varga V1, Rátgéber L4, Boncz I1
1University of Pécs, Pécs, Hungary, 2Babes-Bolyai University Cluj-Napoc, Cluj-Napoca, Romania, 3University of Novi Sad, Novi Sad, Serbia, 4Ratgeber Academia, Pécs, Hungary

PHP240
G8
FOLLOW-UP ANALYSIS OF VALIDITY OF BIA FOR DRUGS TEMPORARILY REIMBURSED IN MODE OF COVERAGE WITH EVIDENCE DEVELOPMENT
Zizalova J, Rrahmaniova D, Svorcikova J, Vrubel F
Ambruz & Dark Deloitte Legal, Prague 8, Czech Republic

PHP241
G9
HEALTH INSURANCE-RELATED ASPECTS OF HOME-BASED PARENTERAL NUTRITION IN HUNGARY
Gresz M1, Endrei D2, Csákvári T3, Danku N2, Sebestyén A4, Horváth L2, Boncz I2
1National Healthcare Service Center, Budapest, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pécs, Zalaegerszeg, Hungary, 4National Health Insurance Fund Administration, Pécs, Hungary

PHP242
G10
OPTIMISING ADVERTS AND CAMPAIGNS FOR EFFICIENT AND COST-EFFECTIVE PATIENT RECRUITMENT USING SOCIAL MEDIA
Wade AG, Crawford GM, McLennan K
Patients Direct, Glasgow, UK

PHP243
G11
TREND OF PHARMACOECONOMICS AND HEALTH OUTCOME STUDIES IN TURKEY
Kockaya G1, Yenilmez FB2, Tuna E3
1Health Economics and Policy Association, Ankara, Turkey, 2Hacettepe University, Ankara, Turkey, 3Polar Health Economics and Policy Consultancy, Ankara, Turkey

PHP244
G12
COST MINIMISATION ANALYSIS: WHEN AND WHERE? A REVIEW OF HTA GUIDANCE ON COST MINIMISATION ANALYSIS
Hirst A, Vlachaki I, Shephard C
WG Access Ltd, London, UK

PHP245
G13
COST-EFFICIENCY OF CLINICAL PHARMACY SERVICES AT MINISTRY OF HEALTH IN SAUDI ARABIA APPLICATION OF AMERICAN MODEL
Alomi YA
Ministry of Health, Riyadh, Saudi Arabia

PHP246
G14
THE VALUE OF PATIENT REPORTED OUTCOMES IN GERMAN AMNOG DOSSIERS
Borchert K, Altevers J, Braun S, Mittendorf T
Xcenda GmbH, Hannover, Germany

PHP247
G15
ASSESSMENT OF WILLINGNESS TO PAY FOR CONSULTAION AND DIAGNOSTIC SERVICES IN SHEIKH KHALIFA BIN ZAYYED AL-NAYYAN MEDICAL COMPLEX, QUETTA
Ahmed N, Haq N, Nasim A
University of Balochistan, Quetta, Pakistan

PHP248
G16
EVALUATION OF CLINICAL AND ECONOMIC IMPACT OF DRUG RELATED PROBLEMS IN ELDERLY PATIENTS AT TERTIARY CARE HOSPITAL
Madhan R1, Vineetha M2
1JSS College of Pharmacy, Mysore, JSS University, MYSORE, India, 2JSS College of Pharmacy, JSS University, MYSORE, India

PHP249
G17
LINGUISTIC VALIDATION OF THE FINNISH VERSION OF THE MODIFIED MOBILITY SECTION OF THE PROSTHESIS EVALUATION QUESTIONNAIRE
Repo JP, Barner-Rasmussen I
University of Helsinki and Helsinki University Hospital, Helsinki, Finland

PHP250
G18
QUANTIFICATION OF QUALITY OF LIFE DIFFERENCES DUE TO COMMON DISEASES IN THE AGE GROUP 50+ IN THE UNITED KINGDOM
Reinders P1, Zoellner YF2, Wood R1, Holbrook T1, Piercy J1
1Adelphi Real World, Bollington, UK, 2Hamburg University of Applied Sciences, Hamburg, Germany

PHP251
WITHDRAWN

PHP252
G19
HOW BENEFICIAL IS HRQOL ASSESSMENT IN THE COURSE OF TREATMENT DECISIONS IN PHYSICAL REHABILITATION? RESULTS OF CLINICIANS' PERSPECTIVE
Meyer-Moock S, Feng Y, Kohlmann T
University Medicine Greifswald, Greifswald, Germany

PHP253
G20
ICPC-2 EPISODE-BASED HEALTH-RELATED QUALITY OF LIFE AND THREE MONTHS EFFECTIVENESS IN THREE FINNISH PRIMARY HEALTH CARE SETTINGS
Soini EJ1, Heinonen J2, Miettola E2, Ryynänen O3, Koskela T4
1ESIOR Oy, Kuopio, Finland, 2School of Medicine, University of Tampere, Finland, 3Faculty of Health Sciences, University of Eastern Finland, and Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, 4Department of General Practice, University of Tampere, and Omapihlaja, Pihlajalinna Terveys Oy, Tampere, Finland

PHP254
G21
INVESTIGATING THE PERCEPTIONS OF THE GREEK POPULATION TOWARDS THE EFFICACY AND SAFETY OF GENERIC DRUGS
Charonis A1, Balasopoulos T1, Naoum P1, Mavrikou M1, Karokis A2, Athanasakis K1, Pavi E1, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2MSD Greece, Athens, Greece

PHP255
G22
CHANGES IN THE CAPACITY OF NEUROLOGICAL AND PSYCHIATRIC INPATIENT CARE IN HUNGARY BETWEEN 1990 AND 2014
Ágoston I1, Endrei D1, Molics B1, Szarka E1, Csákvári T2, Gyuró M1, Boncz I1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary

PHP256
G23
KNOWLEDGE, ATTITUDE AND PERCEPTION OF ZIKA VIRUS AMONG HEALTHCARE STUDENTS OF MEDICINE, PHARMACY AND DENTISTRY OF AIMST UNIVERSITY
Iqbal MZ1, Lokanayagi a/p SS1, Rahul R2, Sunil Kumar P1, Tahir M3
1AIMST University,, Bedong, Kedah Darul Aman, Malaysia, Malaysia, 2Faculty of Dentistry, AIMST University, Sungai Petani, Malaysia, 3University of Veterinary and Animal Sciences, Lahore, Pakistan;, Lahore, Pakistan

PHP257
G24
NUMBER OF PATIENTS IN PHYSIOTHERAPY SERVICES WITHIN SPECIALIZED HOME CARE IN HUNGARY BETWEEN 2010 AND 2014
Járomi M1, Simon-Ugron Á2, Mihajlovic I3, Rátgéber L4, Juhász K5, Sebestyén A5, Endrei D1, Boncz I1, Molics B1
1University of Pécs, Pécs, Hungary, 2Babes-Bolyai University Cluj-Napoc, Cluj-Napoca, Romania, 3University of Novi Sad, Novi Sad, Serbia, 4Ratgeber Academia, Pécs, Hungary, 5National Health Insurance Fund Administration, Pécs, Hungary

PHP258
G25
HEALTH RISK OF DRUGS AND ITS IMPACT ON PATIENT ADHERENCE TO MEDICAL TREATMENT
Masarykova L, Lehocka L, Olearova A, Snopkova M, Buszekova B
Comenius University in Bratislava, Faculty of Pharmacy, Bratislava, Slovakia

PHP259
G26
TASKS INVOLVED IN PLATELET PRODUCTION AND TRANSFUSION FROM THE U.S. HOSPITAL PERSPECTIVE: TWO PROCESS FRAMEWORKS
Prioli KM, Lyons NM, Pizzi LT
Thomas Jefferson University, Philadelphia, PA, USA

PHP260
G27
AUTOMATION OF HOSPITAL MEDICATION DISTRIBUTION SYSTEMS IN THE US
Badawoud EM1, Seoane-Vazquez E1, Alhamdan HS2, Jacobson S1
1MCPHS University, Boston, MA, USA, 2King Abdulaziz Medical City, Jeddah, Saudi Arabia

PHP261
G28
ASSESSMENT OF KNOWLEDGE, ATTITUDE AND PRACTICE (KAP) OF PHARMACIST REGARDING ADVERSE DRUG REACTION (ADRS) AND PHARMACOVIGILANCE IN PUBLIC HOSPITALS QUETTA
Anwer M, Haq N, Nasim A
University of Balochistan, Quetta, Pakistan

PHP262
G29
PRETESTING AN E-BASED VERSION OF THE OXFORD PARTICIPATION & ACTIVITIES QUESTIONNAIRE (OX-PAQ)
Kelly L1, Dummett S1, Dawson J1, Churchman D2, Fitzpatrick R1, Jenkinson C1, Morley D1
1University of Oxford, Oxford, UK, 2Clinical Outcomes at Oxford University Innovation, Oxford, UK

PHP263
G30
EXPLORING THE SOCIOECONOMIC IMPACT OF POST APPROVAL CHANGE REQUIREMENTS FOR VACCINES
Angelis A, Mills M, Lange A, Kanavos P
London School of Economics and Political Science, London, UK

PHP264
G31
PREVALENCE, PERCEPTION AND REASONS FOR SELF MEDICATION
Jan SU1, Gul R2, Mustafa G1, Shah A2
1University of Balocistan, Quetta, Pakistan, 2University of Balochistan, Quetta, Pakistan

PHP265
G32
PRO INSTRUMENTS USED IN STUDIES PUBLISHED SINCE 2005: WHICH POPULATIONS AND DISEASES HAVE HAD THE MOST TOOLS DEVELOPED?
Martin A
Crystallise Ltd., London, UK

PHP266
G33
NICE COLLATERAL EFFECT: WHAT IS THE INFLUENCE OF NICE ON OTHER HTA BODIES?
Wijnands T1, Kreeftmeijer J1, Kooreman PJ1, Wagner P2, van Engen A1
1Quintiles Advisory Services, Hoofddorp, The Netherlands, 2Quintiles Advisory Services, Neu-Isenburg, Germany

PHP267
G34
ADHERENCE TO VANCOMYCIN THERAPEUTIC GUIDELINES AT MINISTRY OF HEALTH HOSPITAL IN SAUDI ARABIA
Alomi YA, Almudaiheem HY
Ministry of Health, Riyadh, Saudi Arabia

PHP268
G35
WITHDRAWN

PHP269
G36
DEXHELPP - AGING POPULATION: ROUTINE DATA BASED ANALYSES OF FRACTURES DUE TO FALLS LESS THAN THREE METERS – HOSPITALIZATION, READMISSION AND MORTALITY
Zauner G1, Wilbacher I2, Popper N3, Breitenecker F4
1dwh GmbH, Vienna, Austria, 2Main Association of Austrian Health Security Institutions, Vienna, Austria, 3DEXHELPP, Vienna, Austria, 4TU Wien, Vienna, Austria

PHP270
G37
ATTRIBUTES DEFINING PATIENT ENGAGEMENT AND CENTEREDNESS IN HEALTH CARE RESEARCH AND PRACTICE: A FRAMEWORK DEVELOPED BY THE ISPOR PATIENT-CENTERED SPECIAL INTEREST GROUP
Hanna ML1, Oehrlein EM2, Perfetto EM2, Astratinei V3, Berner T4, Burke LB5, Camp R6, Hareendran A7, Harrington R8, Houÿez F9, Patrick DL10, Scott A11, von Gizycki R12, Wheeler R13
1School of Pharmacy, University of Maryland, Baltimore, MD, USA, 2University of Maryland, School of Pharmacy, Baltimore, MD, USA, 3Melanom Romania, Bucharest, Romania, 4Baxalta, Bannockburn, IL, USA, 5Study Endpoints and Labeling Development, ONDIO, CDER, U.S. Food & Drug Administration, Silver Spring, MD, USA, 6European Patients' Academy (EUPATI), Barcelona, Spain, 7Evidera, London, UK, 8Astellas Medical Affairs Americas, Northbrook, IL, USA, 9EURORDIS, Paris, France, 10University of Washington, Seattle, WA, USA, 11SEAS Capital Partners, Plymouth, MI, USA, 12Pro Retina Europe, Berllin, Germany, 13Leber Hereditary Optic Neuropathy, Winchester, UK

PHP271
G38
PHARMACOTHERAPY CONSULTATIONS BY CLINICAL PHARMACISTS TO IMPROVE QUALITY AND SAFE USE OF MEDICINES: AN EXPERIENCE FROM TERTIARY CARE TEACHING HOSPITAL
Himanshu Patel ., Parthasarathi G ., Madhan R
JSS College of Pharmacy, Mysore, JSS University, Mysore, India

PHP272
H1
ADVANCED THERAPIES: WIDENING THE GAP BETWEEN PAYERS AND REGULATORS
Hanna E1, Rémuzat C2, Auquier P1, Toumi M1
1Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France, 2Creativ-Ceutical, Paris, France

PHP273
H2
MASTERS DEGREES FOR HEALTH ECONOMISTS: INVESTIGATING AND EVALUATING THEIR CONTENT
Mildred M
University of Sheffield, Sheffield, UK

PHP274
H3
A FRAMEWORK TO GUIDE THE USE OF REAL-WORLD EVIDENCE TO SUPPORT EVALUATION OF RELATIVE EFFECTIVENESS OF NEW MEDICINES
Stegenga H1, Chambers M2, Jonsson P3, Thwaites R4, Garner S5
1National Institute for Health and Care Excellence, London, UK, 2MCHCE, London, UK, 3National Institute for Health and Care Excellence (NICE), Manchester, UK, 4Takeda, London, UK, 5National Institute for Health and Care Excellence (NICE), London, UK

PHP275
H4
JAPAN HEALTH CARE ACT REFORM: TOWARD DECENTRALIZATION AND INTEGRATED HEALTH CARE SYSTEM
Toumi M1, Fukushima A2, Murata K2, Onishi Y2
1Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France, 2Creativ-Ceutical, Tokyo, Japan

HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment Programs
PHP276
H5
UNDERSTANDING HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES IN MAJOR EUROPEAN MARKETS: SYSTEMATIC EVALUATION IN 10 EU COUNTRIES
Nanavaty M, Nyandege A, Gala S, Ramesh V, Shah S
Market Access Solutions LLC, Raritan, NJ, USA

PHP277
H6
CONCORDANCE OF HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS OF DIABETES, HEPATITIS, ONCOLOGY AND EPILEPSY PHARMACEUTICAL PRODUCTS BY FIVE AGENCIES WITHIN EUROPE: AN INTERRATER RELIABILITY AND ASSOCIATION ANALYSIS
Abugri I1, Braun D1, Manfred E1, Gerbsch N2
1Cardiff University in collaboration with Hochschule Fresenius, Idstein, Germany, 2Bundesverband der Pharmazeutischen Industrie e.V, Berlin, Germany

PHP278
H7
CADTH’S $50,000 COST-EFFECTIVENESS THRESHOLD: FACT OR FICTION?
Griffiths EA1, Vadlamudi NK2
1PAREXEL, London, UK, 2PAREXEL, Hyderabad, India

PHP279
H8
NON-PARAMETRIC APPROACH TO ESTIMATING EXPECTED VALUE OF PERFECT INFORMATION: THE USEFULNESS OF THIS APPROACH TO A NATIONAL HTA AGENCY
McCullagh LM1, Schmitz S2, Barry M2, Walsh C3
1Trinity College Dublin, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Ireland, 3University of Limerick, Limerick, Ireland

PHP280
H9
REVIEW OF THE RECOMMENDATIONS MADE BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND THE SCOTTISH MEDICIAL CONSORTIUM (SMC) RELATING TO TREATMENTS FOR RARE DISEASES
Garcia Sanchez JJ, Hill CA
MAP BioPharma Limited, Cambridge, UK

PHP281
H10
WHAT ARE THE MOST IMPORTANT DECISION-MAKING CRITERIA FOR INNOVATIVE HEALTH TECHNOLOGY INTEGRATION? A NATIONAL SURVEY FROM FRENCH HOSPITALS DECISION-MAKERS
Piazza L1, Balayssac D2, Bertaux A3, Deniès F4, Dutheil J5, Dutot C6, Huot L7, Martelli N8, Oliveri V9, Poder T10, Hayes N1
1Bordeaux University Hospital, Talence, France, 2Clermont-Ferrand University Hospital, Clermont-Ferrand, France, 3Dijon University Hospital, Dijon, France, 4Lille University Hospital, Lille, France, 5Caen University Hospital, Caen, France, 6Montpellier University Hospital, Montpellier, France, 7Hospices Civils de Lyon, Lyon, France, 8European Georges Pompidou Hospital, Paris, France, 9Nice University Hospital, Nice, France, 10CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada

PHP282
H11
NICE’S CRITERIA FOR END-OF-LIFE THERAPIES: IS THERE A FOURTH HURDLE TO OVERCOME?
Griffiths EA
PAREXEL, London, UK

PHP283
H12
HEALTH TECHNOLOGY ASSESSMENT IN ARGENTINA: AT WHAT POINT IN THE LIFE-CYCLE OF TECHNOLOGIES ARE THEY REQUESTED
Alcaraz A, Hernández-Vásquez A, Calderón M, Augustovski F, Pichon-Riviere A
Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

PHP284
H13
MULTI-CRITERIA DECISION ANALYSIS (MCDA): COMMON TOOLS FOR DIFFERENT NEEDS SUPPORTING HEALTHCARE DECISION MAKING IN SPAIN
Gilabert-Perramon A1, Betolaza JI2, March JC3, Espín J3, Merino-Montero S4, Gil A4, Badia X4
1Catalan Health Service, Government of Catalonia, Barcelona, Spain, 2Health Department of Basque Government, Vitoria - Gasteiz, Spain, 3Escuela Andaluza de Salud Pública, Granada, Spain, 4Omakase Consulting, Barcelona, Spain

PHP285
H14
THE USE OF CONSENSUS TECHNIQUES TO INFORM HEALTH TECHNOLOGY APPRAISALS
Gammon A, Legarreta L, Paterson G, Strachan S, Davies J
Hayward Medical Communications, Newmarket, UK

PHP286
H15
PRODUCTS OUTSIDE THE GENERAL REIMBURSEMENT SYSTEMS – A SWEDISH AND NORWEGIAN COMPARISON
Dibbern T1, Corcoran K1, Medin E2
1PAREXEL International, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden

PHP287
H16
IS THERE A THRESHOLD IN FRANCE?: FIRST EXHAUSTIVE REVIEW OF PUBLISHED HEALTH-ECONOMIC APPRAISALS BY THE HAUTE AUTORITE DE SANTE (HAS), (FRENCH NATIONAL AUTHORITY FOR HEALTH)
Cartier-Bechu C, Gherardi A, Sivignon M, Pignata M, Petitjean A, Monnier R, Roze S
HEVA HEOR Sarl, Lyon, France

PHP288
H17
ISSUES RELATED TO THE FREQUENCY OF EXPLORATORY ANALYSES BY EVIDENCE REVIEW GROUPS IN THE NICE SINGLE TECHNOLOGY APPRAISAL PROCESS
Kaltenthaler E1, Carroll C1, Hill-McManus D2, Scope A1, Holmes M1, Rice S3, Rose M4, Tappenden P1, Woolacott N5
1University of Sheffield, Sheffield, UK, 2Bangor University, Bangor, UK, 3Newcastle University, Newcastle upon Tyne, UK, 4Southampton University, Southampton, UK, 5University of York, York, UK

PHP289
H18
WITHDRAWN

PHP290
H19
REVIEW OF HEALTH TECHNOLOGY ASSESSMENT (HTA) REQUIREMENTS FOR RARE DISEASES ACROSS EUROPEAN COUNTRIES
Garcia Sanchez JJ, Sattar S, Hill CA
MAP BioPharma Limited, Cambridge, UK

PHP291
H20
KEY DRIVERS OF HTA DECISIONS FOR “LIFE-CHANGING” DRUGS
Jaksa A1, Peress E2, Viana R2
1Context Matters, New York, NY, USA, 2Novartis, Basel, Switzerland

PHP292
H21
BUDGET IMPACT ANALYSIS GUIDELINES: INTERNATIONAL AND HUNGARIAN PERSPECTIVE
Eder B1, Nagy B2
1National Institute of Pharmacy and Nutrition, Budapest, Hungary, 2ELTE University, Budapest, Hungary

PHP293
H22
UNDERSTANDING HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES IN MAJOR LATIN-AMERICAN (LATAM) MARKETS: SYSTEMATIC EVALUATION IN 5 LATAM COUNTRIES
Nanavaty M, Gala S, Nyandege A, Ramesh V, Mwamburi M
Market Access Solutions LLC, Raritan, NJ, USA

PHP294
H23
MULTI-CRITERIA DECISION ANALYSIS TO EVALUATE THE FEMTOSECOND LASER-ASSISTED CATARACT SURGERY IN CHILDREN
Giorgia Tedesco G1, Francesco Faggiano F1, Buzzonetti L2, Petroni S2, Di Pinto G1, Chessa G2, Pietro Derrico P1, Matteo Ritrovato M1
1Bambino Gesù Children's Hospital, Rome, Italy, 2Bambino Gesù Children's Hospital, Fiumicino (Roma), Italy

PHP295
H24
RESULTS OF HTA IN BRAZIL: THE PERFORMANCE OF CONITEC IN ITS FIRST FIVE YEARS
Rabelo RB1, Canuto Santos VC1, Petramale C2, DA Silveira LC1
1Department of Management and Incorporation of Health Technology, National Committee for Health Technology Incorporation (CONITEC), Brazilian Ministry of Health, Brasília, Brazil, 2Department of Management and Incorporation of Health Technology, Ministry of Health of Brazil, Brasília, Brazil

PHP296
H25
SWEDISH PERSPECTIVE ON HEALTH TECHNOLOGY ASSESSMENTS WITH INCREMENTALLY LOWER COSTS AND EFFECTS
Geale K1, Geale K2, Dibbern T2, Virhage M2, Medin E2, Medin E3
1Umeå University, Umeå, Sweden, 2PAREXEL International, Stockholm, Sweden, 3Karolinska Institutet, Stockholm, Sweden

PHP297
H26
CURRENT AND PREFERRED STATUS ON HTA IMPLEMENTATION: A UKRAINIAN PERSPECTIVE
Zalis'ka O, Piniazhko O, Tolubaiev V
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

PHP298
H27
TOWARDS MORE TRANSPARENT HTA PROCESS IN POLAND – NEW POLISH HTA METHODOLOGICAL GUIDELINES
Lach K1, Dziwisz M1, Rémuzat C2, Toumi M2
1Creativ-Ceutical, Krakow, Poland, 2Aix-Marseille University, Marseille, France

PHP299
H28
MARKET ACCESS ROUTES FOR ORPHAN ONCOLOGY DRUGS: HOW DO HEALTH SYSTEMS HELP PATIENTS RECEIVE TREATMENTS THAT ARE NOT COST-EFFECTIVE?
Chevrou-Severac H1, Adkins E2, Solaman DA2, Ratcliffe M2
1Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Switzerland, 2PHMR Ltd, London, UK

PHP300
H29
IS THERE EVIDENCE OF A DIFFERENCE BETWEEN WILLINGNESS TO PAY AND WILLINGNESS TO ACCEPT THRESHOLDS? A REVIEW OF NICE TECHNOLOGY APPRAISALS
Minacori R1, Geale K2
1PAREXEL International, London, UK, 2Umeå University, Umeå, Sweden

PHP301
H30
UNDERSTANDING HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES IN MAJOR ASIA-PACIFIC (APAC) MARKETS: SYSTEMATIC EVALUATION IN 10 APAC COUNTRIES
Nanavaty M, Nyandege A, Gala S, Ramesh V, Mwamburi M
Market Access Solutions LLC, Raritan, NJ, USA

PHP302
H31
SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (NMA) IN REIMBURSEMENT SUBMISSION; WHAT NICE SAYS VERSUS WHAT NICE WANTS
Sarri G1, Rizzo M2, Iheanacho I1
1Evidea, London, UK, 2Evidera, London, UK

PHP303
H32
FIXED-DOSE COMBINATION DRUGS UNDERGOING AMNOG - LEARNINGS FROM 5 YEARS
Froehlich H, Drechsler M
AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany

PHP304
H33
PERCEPTION SURVEY ON HEALTH TECHNOLOGY ASSESSMENT IN TURKEY: DOES PRACTICE MEET WITH REGULATIONS
Koselerli R1, Caliskan Z2, Kuzucu G3, Gursoy K1, Ergun H4, Kaya Y5, Turkoglu S6, Dereli U7, Koksal T8, Deger C7, Dokuyucu O9, Saylan M10
1Turkish Social Security Institution, Ankara, Turkey, 2Hacettepe University, Ankara, Turkey, 3Lundbeck Turkey, Istanbul, Turkey, 4Ankara University, Ankara, Turkey, 5Bristol-Myers Squibb, Istanbul, Turkey, 6Nobel Pharma, Ankara, Turkey, 7Association of Research-Based Pharmaceutical Companies, Istanbul, Turkey, 8Pharmaceutical manufacturers association of Turkey, Ankara, Turkey, 9AMGEN, Istanbul, Turkey, 10Bayer AG Turkey, Istanbul, Turkey

PHP305
H34
G-BA EARLY ADVICE VS. EMA/HTA PARALLEL ADVICE FROM A GERMAN PERSPECTIVE
Wiebe K1, Schmitter S2, Leverkus F2, Heathfield A3
1Pfizer Germany, Berlin, Germany, 2Pfizer Deutschland GmbH, Berlin, Germany, 3Pfizer, Surrey, UK

PHP306
H35
GLOBAL EVALUATION OF EUROPEAN SUBMISSION TEMPLATE TO INFORM HTA AND PAYER SUBMISSIONS
Tatt ID, Gyldmark M, Correia HC
F.Hoffman-La Roche Ltd, Basel, Switzerland

PHP307
H36
IMPLEMANTATION OF PROCESSES TO ESTABILISHING A HTA UNIT IN CZECH HOSPITAL ENVIROMENT
Zavadil M1, Matlonova V2, Kubatova I2, Rogalewicz V2
1Motol University Hospital, Prague, Czech Republic, 2Czech Technical University in Prague, Kladno, Czech Republic

PHP308
H37
WITHDRAWN

PHP309
H38
“BEST SUPPORTIVE CARE” OR “THERAPY ACCORDING TO PHYSICIAN'S CHOICE” AS APPROPRIATE COMPARATOR FOR GERMAN HTA DOSSIERS – AN UNDERESTIMATED CHANCE OR RISK FOR THE BENEFIT ASSESSMENT?
Eheberg D1, Dannemann S2, Jakovac M3, Bonduelle D1
1IMS Health, Munich, Germany, 2QuintilesIMS, Munich, Germany, Munich, Germany, 3IMS Health Germany, Munich, Germany

PHP310
I1
DIFFERENT METHODS, DIFFERENT RESULTS? COMPARING HEALTH TECHNOLOGY ASSESSMENTS IN THE UNITED KINGDOM AND GERMANY
Schaefer R, Schlander M
Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany

HEALTH CARE USE & POLICY STUDIES - Patient Registries & Post-Marketing Studies
PHP311
I2
IMPACT OF POST-INSCRIPTION STUDIES ON REASSESSMENT IN FRANCE: A CASE STUDY ON ORPHAN DRUGS
Jubert H, Ouali I, Kolahi C
IMS Health, La Défense, France

PHP312
I3
PATIENT INFORMATION AND CONSENT FORM IN EUROPE: REQUIREMENTS FROM REGULATORY AUTHORITIES FOR PHARMACO-EPIDEMIOLOGICAL STUDIES
Baconnier C, Bourhis Y, Logette E, Bugnard F
Mapi, Lyon, France

HEALTH CARE USE & POLICY STUDIES - Population Health
PHP313
I4
THE EFFECT OF PHYSICAL ACTIVITY ON THE MENTAL AND EMOTIONAL STATE OF UNIVERSITY STUDENTS
Fónai A, Makai A, Boncz I, Ács P, Molics B, Gyuró M, Járomi M
University of Pécs, Pécs, Hungary

PHP314
I5
SOCIO-ECONOMIC STATUS AND SELF-RATED HEALTH: ARE THEY GOOD PREDICTORS OF INCOME? AN ANALYSIS OF SURVEY PANEL DATA FROM TURKEY
Cinaroglu S1, Baser O2
1Hacettepe University, Ankara, Turkey, 2Columbia University/MEF University/STATinMED Research, New York, NY, USA

PHP315
I6
UNDERSTANDING THE RELATIONSHIP BETWEEN EFFECTIVENESS AND OUTCOME INDICATORS IN HEALTH CARE
Cinaroglu S1, Baser O2
1Hacettepe University, Ankara, Turkey, 2Columbia University/MEF University/STATinMED Research, New York, NY, USA

HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment Guidelines
PHP316
I7
INFLUENCE OF MEDICAL REPRESENTATIVES ON PRESCRIBING PRACTICES IN MEKELLE, NORTHERN ETHIOPIA
Belay yB
Mekelle University, Mekelle, Ethiopia

PHP317
I8
HOW CAN HEALTHCARE PATHWAYS EXPLAIN POLYPHARMACY IN FRANCE? A LONGITUDINAL ANALYSIS BETWEEN 2011 AND 2014
Louchez A, Perronnin M, Pichetti S, Sermet C
IRDES, Paris, France

PHP318
I9
NATIONAL SURVEY OF DRUG INFORMATION CENTERS PRACTICE IN SAUDI ARABIA: EVIDENCE BASED MEDICINE-THERAPEUTICS GUIDELINES SYSTEM (EBM-TG) AT MOH
Alomi YA, Almudaiheem HY, Alsharari A
Ministry of Health, Riyadh, Saudi Arabia

HEALTH CARE USE & POLICY STUDIES - Quality of Care
PHP319
I10
IMPLEMENTATION OF MEDICATION ERRORS REPORTING SYSTEM BY CLINICAL PHARMACISTS AT TERTIARY CARE TEACHING HOSPITAL: A PILOT STUDY
Ramesh M1, Parthasarathi G .2, Himanshu Patel .2
1JSS College of Pharmacy, JSS University, Mysore, India, Mysore, India, 2JSS College of Pharmacy, Mysore, JSS University, Mysore, India

HEALTH CARE USE & POLICY STUDIES - Regulation of Health Care Sector
PHP320
I11
THE EVALUATION OF RELATIONSHIP BETWEEN REGULAR INSPECTION AND COMMITTING MAJOR MALPRACTICE IN PAKDASHT PHARMACIES
Sabbagh-Bani-Azad M1, Varastehmoradi B2, Nikfar S3
1Tehran University Of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of), 2Shahid Beheshti University Of Medical Sciences, Tehran, Iran (Islamic Republic of), 3Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of)

PHP321
I12
SUPPLY-SIDE AND DEMAND-SIDE POLICIES FOR BIOSIMILARS: AN OVERVIEW IN 10 EUROPEAN MEMBER STATES
Rémuzat C1, Kapuśniak A2, Caban A3, Ionescu D4, Radière G4, Mendoza C4, Toumi M5
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Krakow, Poland, 3Creativ-Ceutical, Cracow, Poland, 4Sandoz International GmbH, Holzkirchen, Germany, 5Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP322
I13
FRENCH HEALTH POLICIES: FRONT RUNNER FOR EARLY ACCESS TO INNOVATION
Rémuzat C1, Thivolet M1, Kornfeld A1, Toumi M2
1Creativ-Ceutical, Paris, France, 2Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP323
I14
HEALTH CARE SYSTEM INEFFICIENCIES RELATED TO MEDICINES: ANY POTENTIAL ROOM FOR IMPROVEMENT?
Rémuzat C1, Toumi M2
1Creativ-Ceutical, Paris, France, 2Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP324
I15
THE DYNAMIC EVOLUTION OF EXTERNAL PRICE REFERENCING IMPLEMENTATION IN VARIOUS COUNTRIES
Fontrier A, Efthymiadou A, Boekstein N, Kanavos P, Gill J
London School of Economics and Political Science, London, UK

PHP325
I16
KEY DRIVERS FOR MARKET PENETRATION OF BIOSIMILARS IN EUROPE
Rémuzat C1, Dorey J1, Cristeau O1, Ionescu D2, Radière G2, Mendoza C2, Toumi M3
1Creativ-Ceutical, Paris, France, 2Sandoz International GmbH, Holzkirchen, Germany, 3Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP326
I17
SETTING RECOMMENDATIONS FOR GOOD PRACTICE OF HEALTH TECHNOLOGY ASSESSMENT IN THE EGYPTIAN MINISTRY OF HEALTH
Griffin A1, Elsisi G2, Ragab S3, Ziada R4, Aboushady R4, Abdelgawad S4, Atef M3, Khataby N3, Ashraf RM5
1Johnson & Johnson, High Wycombe, UK, 2Central Administration for Pharmaceutical Affairs, Cairo, Egypt, 3Ministry of Health, Cairo, Egypt, 4Central Administration for Pharmaceutical Affairs, cairo, Egypt, 5Janssen, Cairo, Egypt

PHP327
I18
A PROSPECTIVE ASSESSMENT OF ATTITUDES AND EXPERIENCES AMONG UROLOGISTS REGARDING OFF LABEL USE OF BCG VACCINE IN SERBIA
Marinkovic V1, Bekcic S2, Djordjevic J3, Tasic L1, Stojkovic T1
1University of Belgrade-Faculty of Pharmacy, Belgrade, Serbia, 2Research and Technology Center, Novi Sad, Serbia, 3Alvogen d o o, Belgrade, Serbia

PHP328
I19
THE IMPACT OF EXTERNAL PRICE REFERENCING WITHIN AND ACROSS A COUNTRY'S BORDERS
Fontrier A, Efthymiadou A, Boekstein N, Kanavos P, Gill J
London School of Economics and Political Science, London, UK

PHP329
I20
OBSTACLES FOR ADOPTION OF VALUE ADDED MEDICINES: CALL FOR POLICY CHANGES FOR VALUE RECOGNITION OF REPURPOSED MEDICINES
Rémuzat C1, Toumi M2
1Creativ-Ceutical, Paris, France, 2Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP330
I21
HOW DO COST-CONTAINMENT MEASURES IMPACT PHARMACEUTICAL INDUSTRY?
Zimmermann N, Gombocz M, Vogler S
Gesundheit Österreich GmbH / Austrian Public Health Institute, Vienna, Austria

PHP331
I22
ARE DRUG PROCUREMENT PROCEDURE AND AWARD CRITERIA IN EU HOSPITAL SETTING STANDARDIZED AND DO THEY TAKE INTO ACCOUNTS EFFECTIVE SUPPLY QUALITY?
Triulzi I, Trieste L, Turchetti G
Scuola Superiore Sant'Anna, Pisa, Italy

PHP332
I23
REAL WORLD EVIDENCE IN EUROPE: A SNAPSHOT OF ITS CURRENT STATUS
Olariu E, Papageorgakopoulou C, Bovens SM, Solaman DA, Fox D
PHMR Ltd, London, UK

HEALTH CARE USE & POLICY STUDIES - Risk Sharing/Performance-Based Agreements
PHP333
I24
THE EVOLUTION OF RISK-SHARING AGREEMENTS IN THE PROCESS OF UPDATING THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL
Triki N1, Ash N1, Porath A1, Birnbaum Y2, Greenberg D3, Hammerman A2
1Maccabi Healthcare Services, Tel-Aviv, Israel, 2Clalit Health Services, Tel-Aviv, Israel, 3Ben-Gurion University of the Negev, Beer Sheva, Israel

PHP334
I25
INNOVATIVE CONTRACTING IN SPAIN (2010-2016). GETTING MORE "IN"
Gimenez E1, Badia X1, Gil A1, Espinosa C2
1Omakase Consulting, Barcelona, Spain, 2Ferrer, Barcelona, Spain

PHP335
I26
INSIGHTS FROM 6 YEARS' MANAGED ENTRY AGREEMENT EXPERIENCE IN BELGIUM
Quanten A, Van de Vijver I, Knappenberg V, Arickx F, De Ridder R
National Institute for Health and Disability Insurance (NIHDI), Brussels, Belgium

PHP336
I27
SUCCESS AND FAILURE OF STRAIGHTFORWARD VERSUS SOPHISTICATED MANAGED ENTRY AGREEMENTS
Van de Vijver I, Quanten A, Knappenberg V, Arickx F, De Ridder R
National Institute for Health and Disability Insurance (NIHDI), Brussels, Belgium

PHP337
I28
THE QUEV SCORE: A QUANTITATIVE EVALUATION OF THE QUALITY OF CLINICAL EVIDENCE IN HTA
Schmitz S1, McCullagh L2, Walsh C3, Dolan E4
1Luxembourg Institute of Health, Strassen, Luxembourg, 2Trinity College, Dublin, Ireland, 3University of Limerick, Limerick, Ireland, 4Royal College of Surgeons in Ireland, Dublin, Ireland

PHP338
I29
SIMILARITIES AND DIFFERENCES OF RISK SHARING ARRANGEMENTS IN AUSTRALIA, UNITED KINGDOM, ITALY, AND KOREA
Kim S, Kim A, Bae S
Ewha Womans University, Seoul, South Korea

PHP339
I30
RISK SHARING AGREEMENTS (RSA): EXPLORATORY ANALYSIS OF THE CURRENT SITUATION IN DEVELOPED AND EMERGING MARKETS
Saggia MG
Asigma, Sao Paulo, Brazil

PHP340
I31
MARKET ACCESS AGREEMENTS: WHAT IMPACTS DRUGS PURCHASING IN FRENCH HOSPITALS
Ceyrac T1, Poisson N1, Tilleul P2, Paubel P1
1General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 2Hospital Pitie-Salpetriere, Paris, France

PHP341
I32
MANAGED ENTRY AGREEMENTS: PORTUGUESE EXPERIENCE
Gonçalves L, Teixeira M, Caldeira S, Ramos R
INFARMED, I.P., Lisbon, Portugal

PHP342
I33
A RISK-BENEFIT ANALYSIS OF KEY PERFORMANCE-BASED RISK SHARING AGREEMENTS (PBRSAS) IN THE EU AND US (2002-2016)
Carroll E, Truglio A
GfK, New York, NY, USA

PHP343
I34
TYPES OF RISK-SHARING SCHEMES PROPOSED IN REIMBURSEMENT APPLICATION RECEIVED BY AOTMIT IN 2015
Pomorski MK, Matusewicz W, Lipińska A
Agency for Health Technology Assessment and Tariff System, Warsaw, Poland

PHP344
I35
CREATING USEFUL AND COMPREHENSIVE DECISION SUPPORT TOOLS FOR SELECTING AND DESIGNING MANAGED ENTRY AGREEMENTS
Lucas F
Pope Woodhead & Associates Ltd, St. Ives, UK

PHP345
I36
DEFINING EPISODES OF CARE FOR CHRONIC DISEASES: A TARGETED LITERATURE REVIEW
Ng DB1, Sherman S2, Desroziers K3, Gooch K1
1Astellas Pharma Global Development, Inc., Northbrook, IL, USA, 2Creativ-Ceutical, Chicago, IL, USA, 3Creativ-Ceutical, Paris, France

PHP346
I37
A NEW COVERAGE WITH EVIDENCE DEVELOPMENT DEDICATED TO INNOVATIVE MEDICAL BIOLOGY AND PATHOLOGICAL ANATOMY AND CYTOLOGY PROCEDURES IN FRANCE: OVERVIEW OF THE SITUATION AFTER ONE YEAR OF IMPLEMENTATION AND FOCUS ON INNOVATIVE GENETICS PROCEDURES
Sam E, Carbonneil C
French Ministry of Health, General Directorate for Healthcare Provision (DGOS/PF4), Paris, France

PHP347
J1
COUNTRY TRENDS THAT MAY IMPACT THE COMMERCIAL OPPORTUNITY OF NEW HIGH COST TREATMENTS IN THE USA, EU5, JAPAN AND BRAZIL
Klebba S1, Pacheco L2, Czira A1, Panciera D3
1GfK, London, UK, 2GfK Market Access, London, UK, 3GfK UK Ltd, London, UK

PHP348
J2
WITHDRAWN

PHP349
J3
IMPACT OF TRIAL DESIGN ON PRICE DISCOUNTS AFTER EARLY BENEFIT ASSESSMENT (AMNOG) IN GERMANY
Theidel U, Löpmeier J, Mittendorf T
Xcenda GmbH, Hannover, Germany

PHP350
J4
POLICIES FOR USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT: A COMPARATIVE STUDY OF 6 HTA AGENCIES
Makady A1, ten Ham R2, de Boer A3, Hillege JL4, Klungel O2, Goettsch W1
1The National Healthcare Institute (ZIN), Diemen, The Netherlands, 2Utrecht University, UTRECHT, The Netherlands, 3Utrecht University, Utrecht, The Netherlands, 4University Medical Center Groningen, Groningen, The Netherlands

PHP351
J5
WHAT IS REAL-WORLD DATA?: A REVIEW OF DEFINITIONS BASED ON LITERATURE & STAKEHOLDER INTERVIEWS
Makady A1, de Boer A2, Hillege JL3, Klungel O4, Goettsch W1
1The National Healthcare Institute (ZIN), Diemen, The Netherlands, 2Utrecht University, Utrecht, The Netherlands, 3University Medical Center Groningen, Groningen, The Netherlands, 4Utrecht University, UTRECHT, The Netherlands

HEALTH CARE USE & POLICY STUDIES - Conceptual Papers
PHP352
J6
THE NICE ACCELERATED ACCESS REVIEW, HOW DOES IT COMPARE TO THE DUTCH CONDITIONAL REIMBURSEMENT PATHWAY?
Bovens SM, Solaman DA, Crutwell JR, Adkins E, Ratcliffe M
PHMR Ltd, London, UK

PHP353
J7
COULD AMNOG BECOME IRRELEVANT IN THE 21ST CENTURY? POTENTIAL REDUNDANCIES IN THE AMNOG PROCESS IN THE ERA OF CURATIVE THERAPIES
Macaulay R
Parexel Access Consulting, London, UK

PHP354
J8
ROMANIAN CLAW-BACK TAXATION: FROM A FINANCIAL SOLUTION TO A CHALLENGE FOR PATIENTS ACCESS TO DRUGS
Radu PC, Chiriac ND, Pravat MA
Roche Romania Srl, Bucharest, Romania

PHP355
J9
GENERATING CONSISTENT AND RELIABLE EVIDENCE ON SURVIVAL ESTIMATES FOR HEALTH TECHNOLOGY ASSESSMENT IN ONCOLOGY AND HAEMATOLOGY
Grouin J1, Rose M2, Magrez D3, Tehard B3, Bardet A3
1University of Rouen - INSERM 1219 « Population Health », Mont-Saint-Aignan, France, 2Celgene, Paris La Défense Cedex, France, 3Roche, Boulogne-Billancourt, France

PHP356
J10
ADOPTION OF ONCOLOGY BIOSIMILARS IN EUROPE
Grosvenor AS, Saraf S, Vidal Pinheiro A, Vithlani M
Precision for Value, London, UK

PHP357
J11
ACCESS TO NEW HEALTH TECHNOLOGIES IN THE BRAZILIAN HEALTH SYSTEM: DISSEMINATING INFORMATION TO LAW OPERATORS FOR QUALIFYING THE HEALTH DECISIONS
Silva SN1, Rabelo RB2, Simabuku EM3, Canuto Santos VC2
1Ministry of Health, Brasilia, Brazil, 2Department of Management and Incorporation of Health Technology, National Committee for Health Technology Incorporation (CONITEC), Brazilian Ministry of Health, Brasília, Brazil, 3Brazilian Ministry of Health, Brasilia, Brazil

PHP358
J12
THE IMPACT ON ACCESS TO INNOVATIVE DRUGS OF THE FIRST MANAGED ENTRY AGREEMENTS IN ROMANIA
Chiriac ND, Radu PC, Pravat MA
Roche Romania Srl, Bucharest, Romania

PHP359
J13
LAUNCHING NOVEL ANTIBIOTICS: ACCESS OPPORTUNITIES AND RESISTANCE IN EUROPEAN MARKETS
Hakim P1, Gilbane A2, Schlegel R2
1Navigant Consulting Inc, London, UK, 2Navigant Consulting Inc., London, UK

PHP360
J14
MACRO-ECONOMIC CONSIDERATIONS IN HEALTHCARE DECISION MAKING
Eggleston A1, Caputo J2
1E.K.K.A. Health Care Consulting, Sydney, Australia, 2ESSEC Asia-Pacific, Singapore, Singapore

PHP361
J15
THE USE OF THE APPRAISAL OF GUIDELINES FOR RESEARCH AND EVALUATION II (AGREE II) TOOL FOR APPRAISAL OF MULTIPLE MYELOMA TREATMENT GUIDELINES
Orzel K, Strzelec E, Pelczarska A, Zawada A, Matusewicz W
The Agency for Health Technology Assessment and Tariff System, Warsaw, Poland

PHP362
J16
STANDARDISATION AND COMPATIBILITY BETWEEN HTA NETWORKS: WHAT IMPACTS ON QUALITY?
Pacheco L
GfK Market Access, London, UK

PHP363
J17
CHALLENGES FOR HTA SUBMISSIONS CONCERNING CONDITIONS LACKING ESTABLISHED TREATMENT PATHWAYS
Adkins E, Fountain DL, Bovens SM
PHMR Ltd, London, UK

PHP364
J18
THE EVALUATION OF INNOVATIVE DRUGS APPLYING BUSINESS VALUATION CONCEPTS
Nuijten MJ1, Vis J2
1A2M, Amsterdam, The Netherlands, 2Talanton, Amsterdam, The Netherlands

PHP365
J19
UNLOCKING ESTABLISHED PRODUCTS PATIENT AND SOCIETAL VALUE IN ADDITIONAL INDICATIONS
Nayroles G1, Gabriel S1, Toumi M2, Kornfeld A3, Frybourg S3, Antonanzas F4, Espin J5, Jommi C6, de Pouvourville G7, Tolley K8, Wasem J9
1IPSEN Pharma, Boulogne-Billancourt, France, 2Aix-Marseille University, Marseille, France, 3Creativ-Ceutical, Paris, France, 4University of La Rioja, Logroño, Spain, 5Andalusian School of Public Health, Granada, Spain, 6Cergas, Bocconi University, Milano, Italy, 7ESSEC Business School, Cergy-Pontoise, France, 8Tolley Health Economics, Buxton, UK, 9University Duisburg-Essen, Essen, Germany

PHP366
J20
PHARMACEUTICAL TRACKING SYSTEM: AN IMPROVEMENT IN DATA ACCURACY AND USES
Afify Y
Ministry of Health, Cairo, Egypt

PHP367
J21
MAPPING OF THE BIOSIMILAR DRUG POLICY IN 10 CENTRAL EASTERN EUROPEAN COUNTRIES
Inotai A1, Csanadi M1, Petrova G2, Bochenek T3, Tesar T4, York K5, Fuksa L6, Kostyuk A7, Araja D8, Lorenzovici L9, Egyed K10, Kaló Z11
1Syreon Research Institute, Budapest, Hungary, 2Medical University-Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 3Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland, 4Department of Organisation and Management in Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia, 5Independent, Innsbruck, Austria, 6Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Hradec Králové, Czech Republic, 7Kazakh Agency for Health Technology Assessment, Astana, Kazakhstan, 8Riga Stradins University, Riga, Latvia, 9Syreon Research Romania, Tirgu Mures, Romania, 10Egis Pharmaceuticals, Budapest, Hungary, 11Eötvös Loránd University (ELTE), Budapest, Hungary

PHP368
J22
BEYOND RISK-BASED VACCINATION POLICIES - A LIFE-COURSE APPROACH TO VACCINATION
Lach K1, Jaroslawski S2, Pisarczyk K1, Toumi M2
1Creativ-Ceutical, Krakow, Poland, 2Aix-Marseille University, Marseille, France

PHP369
WITHDRAWN

PHP370
J23
BALANCING COMMERCIAL CONFIDENTIALITY WITH ACCOUNTABILITY: A PROPOSAL FOR ENHANCED DISCLOSURE OF COST-EFFECTIVENESS DECISIONS
O'Mahony JF
Trinity College Dublin, Dublin, Ireland

PHP371
J24
LEGISLATIVE FRAMEWORK FOR REIMBURSEMENT CONDITIONS FOR GENE THERAPIES
Ligri D1, Kani C2, Souliotis K2
1Aristotle University of Thessaloniki, Thessaloniki, Greece, 2University of Peloponnese, Corinth, Greece

PHP372
J25
MANAGED ACCESS AGREEMENTS: A NEW MODEL PATHWAY FOR THE REIMBURSEMENT OF NON-ONCOLOGY DRUGS IN ENGLAND APPROVED UNDER EUROPEAN ADAPTIVE PATHWAYS?
Macaulay R
Parexel Access Consulting, London, UK

PHP373
J26
USING SOCIAL FINANCE TO FUND GENERIC DRUG REPURPOSING FOR RARE DISEASES: A SOCIAL IMPACT BOND PROOF OF CONCEPT
Thompson RS1, Potter J2, Griffiths A3, Eljamel S3, Raffai F1, Sireau NT1
1Findacure, Cambridge, UK, 2Numbers for Good, London, UK, 3Costello Medical Consulting Ltd, Cambridge, UK

PHP374
J27
STRATEGIC CONSIDERATIONS TO ENGAGE IN EARLY ADVICE WITH EUROPEAN HEALTH TECHNOLOGY ASSESSMENT BODIES
Rémuzat C1, Kornfeld A1, Thivolet M1, Toumi M2
1Creativ-Ceutical, Paris, France, 2Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille, France

PHP375
J28
EUROPEAN REGULATORS AND PAYERS INITIATIVES FOR DRUG ACCESS: COLLABORATIONS OR DIVERGENCES?
Rémuzat C1, Kornfeld A1, Falissard B2, Toumi M3
1Creativ-Ceutical, Paris, France, 2INSERM Unit U669 (Public Health and Mental Health), University Paris-Sud, Maison de Solenn, Paris, France, 3Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP376
J29
COULD EUROPEAN REGULATORS CONTRIBUTE TO DRUG BUDGET CONTAINMENT?
Rémuzat C1, Thivolet M1, Falissard B2, Toumi M3
1Creativ-Ceutical, Paris, France, 2INSERM Unit U669 (Public Health and Mental Health), University Paris-Sud, Maison de Solenn, Paris, France, 3Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PHP377
J30
COMPARATIVE ANALYSIS OF THE GUIDELINES FOR CONDUCTING HTA IN POLAND AND BULGARIA
Benisheva T, Trendafilova PD, Sidjimova DA, Vodenitcharov TV
Medical University-Sofia, Sofia, Bulgaria

PHP378
J31
GETTING MEDICAL INNOVATION TO PATIENTS IN DEVELOPING COUNTRIES - A SYSTEMIC APPROACH TO SETTING PRICE AND ACCESS
Shankar R
IMS Consulting Group, Cambridge, UK

PHP379
WITHDRAWN

PHP380
J32
STRUCTURE OF HTA NETWORKS FROM THE PERSPECTIVE OF NETWORK ECONOMICS
Pacheco L
GfK Market Access, London, UK

PHP381
J33
TOWARD A NEW BUSINESS MODEL FOR BIOSIMILARS
Rémuzat C1, Kornfeld M1, Caban A2, Toumi M3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Cracow, Poland, 3Faculté de Médecine Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille Cedex, France, Marseille, France

PHP382
J34
CHANGE MANAGEMENT OF POLYPHARMACY AND ADHERENCE: THE EXPERIENCE OF EU SIMPATHY PROGRAM
Geitona M1, Balasopoulou A1, Latsou D1, Kousoulakou H1, Vontetsianos T1, Kampolis C1, Gennimata D1, Michael N2, McKenzie D3, Mair A2
1University of Peloponnese, Corinth, Greece, 2SCOTTISH GOVERNMENT, Edinburgh, UK, 3Kite Innovation, Edinburgh, UK

PHP383
J35
ADAPTIVE REIMBURSEMENT MODEL: HOW TO CORRELATE THE PRICE TO THE LEVEL OF EVIDENCES DURING THE ENTIRE DRUG LIFE CYCLE
Deroo V1, Giuliani G1, Era S2, Dotti MC3
1Roche Spa, Monza, Italy, 2Roche Spa, Monza (MB), Italy, 3Roche, Monza, Italy

PHP384
J36
THE CHALLENGE OF CRITICAL MASS TO BE OVERCOME BY INTERNATIONAL HTA NETWORKS
Pacheco L
GfK Market Access, London, UK

PHP385
J37
ETHICAL AND TECHNOLOGICAL EVALUATION OF SECURITY OF CONNECTED OBJECTS AND HEALTH APPLICATIONS: HOW TO MOVE TOWARDS CERTIFICATION
Allaert F
Medical evaluation Chair ESC Dijon, Dijon, France

PHP386
K1
WITHDRAWN

PHP387
K2
PUBLIC CONSULTATION AS A TOOL FOR PATIENT AND PUBLIC INVOLVEMENT IN THE BRAZILIAN HTA PROCESS
Silva AS1, Rabelo RB2, Canuto Santos VC3, Petramale C4
1Brazilian Ministry of Health, Brasilia, Brazil, 2Ministry of Health, Brasilia, Brazil, 3Department of Management and Incorporation of Health Technology, National Committee for Health Technology Incorporation (CONITEC), Brazilian Ministry of Health, Brasília, Brazil, 4Department of Management and Incorporation of Health Technology, Ministry of Health of Brazil, Brasília, Brazil

PHP388
K3
THE IMPORTANCE OF CONITEC RECOMMENDATION ABOUT ANALOGUES INSULINS OF THE TREATMENT OF DIABETES TYPE 1
Simabuku EM1, Silva SN1, Santos VC2, Petramale C3
1Brazilian Ministry of Health, Brasilia, Brazil, 2Department of Management and Incorporation of Health Technology, National Committee for Health Technology Incorporation (CONITEC), Brazilian Ministry of Health, Brasília, Brazil, 3Department of Management and Incorporation of Health Technology, Ministry of Health of Brazil, Brasília, Brazil

PHP389
K4
THE EUROPEAN SOCIAL PREFERENCE MEASUREMENT (ESPM) STUDY: CONCEPTUAL CONSIDERATIONS AND IMPLEMENTATION
Schlander M1, Telser H2, Holm S3, Marshall DA4, Nord E5, Richardson J6, Garattini S7, Kolominsky-Rabas P8, Persson U9, Postma MJ10, Simoens S11, de Sola-Morales O12, Tolley K13, Toumi M14
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany, 2Polynomics AG, Olten, Switzerland, 3University of Manchester, Manchester, UK, 4Alberta Bone and Joint Health Institute, Calgary, AB, Canada, 5Norwegian Institute of Public Health, Oslo, Norway, 6Monash University, Clayton, Victoria, Australia, 7Mario Negri Institute for Pharmacological Research, Milano, Italy, 8Interdisciplinary Centre for Health Technology Assessment and Public Health (IZPH), Friedrich-Alexander-University of Erlangen-Nürnberg; National Leading-Edge Cluster Medical Technologies ‘Medical Valley EMN’, Erlangen, Germany, 9The Swedish Institute for Health Economics (IHE), Lund, Sweden, 10University of Groningen, Groningen, The Netherlands, 11KU Leuven, Leuven, Belgium, 12Health Innovation Technology Transfer, Barcelona, Spain, 13Tolley Health Economics Ltd., Buxton, UK, 14University Claude Bernard Lyon 1, Lyon, France

PHP390
K5
INCREASING EFFICIENCY OF PRICING AND MARKET ACCESS DECISIONS BY CROSS FUNCTIONAL INTERACTIONS
Mukku S, Edathodu A
Access Infinity Ltd, London, UK

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.